Prestige Consumer Healthcare (PBH) 10-Q 4 Feb 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2015	Jan. 29, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Brands Holdings, Inc.
Entity Central Index Key	1,295,947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		52,754,256

Consolidated Statements of Inco

Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Revenues
Net sales	$ 199,485	$ 196,435	$ 596,034	$ 520,981
Other revenues	710	1,171	2,358	3,596
Total revenues	200,195	197,606	598,392	524,577
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	83,411	85,861	249,432	228,424
Gross profit	116,784	111,745	348,960	296,153
Operating Expenses
Advertising and promotion	29,935	30,144	84,250	74,284
General and administrative	18,135	19,454	52,186	63,588
Depreciation and amortization	6,071	5,154	17,478	11,967
Total operating expenses	54,141	54,752	153,914	149,839
Operating income	62,643	56,993	195,046	146,314
Other (income) expense
Interest income	(31)	(20)	(91)	(67)
Interest expense	19,493	24,612	62,104	57,505
Gain on sale of asset	0	(1,133)	0	(1,133)
Loss on extinguishment of debt	0	0	451	0
Total other expense	19,462	23,459	62,464	56,305
Income before income taxes	43,181	33,534	132,582	90,009
Provision for income taxes	15,186	12,241	46,611	35,521
Net income	$ 27,995	$ 21,293	$ 85,971	$ 54,488
Earnings per share:
Basic (in USD per share)	$ 0.53	$ 0.41	$ 1.63	$ 1.05
Diluted (in USD per share)	$ 0.53	$ 0.40	$ 1.62	$ 1.04
Weighted average shares outstanding:
Basic (in shares)	52,824	52,278	52,727	52,110
Diluted (in shares)	53,203	52,730	53,106	52,622
Comprehensive income, net of tax:
Currency translation adjustments	$ 4,922	$ (8,779)	$ (6,562)	$ (16,883)
Total other comprehensive loss	4,922	(8,779)	(6,562)	(16,883)
Comprehensive income	$ 32,917	$ 12,514	$ 79,409	$ 37,605

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Current assets
Cash and cash equivalents	$ 48,973	$ 21,318
Accounts receivable, net	85,085	87,858
Inventories	80,671	74,000
Deferred income tax assets	8,406	8,097
Prepaid expenses and other current assets	5,020	10,434
Total current assets	228,155	201,707
Property and equipment, net	12,302	13,744
Goodwill	282,679	290,651
Intangible assets, net	2,116,511	2,134,700
Other long-term assets	1,352	1,165
Total Assets	2,640,999	2,641,967
Current liabilities
Accounts payable	28,539	46,115
Accrued interest payable	9,359	11,974
Other accrued liabilities	48,823	40,948
Total current liabilities	86,721	99,037
Long-term debt
Principal amount	1,477,500	1,593,600
Less unamortized debt costs	(30,468)	(32,327)
Long-term debt, net	1,447,032	1,561,273
Deferred income tax liabilities	383,485	351,569
Other long-term liabilities	2,823	2,464
Total Liabilities	$ 1,920,061	$ 2,014,343
Commitments and Contingencies
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	$ 0	$ 0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 53,059 shares at December 31, 2015 and 52,562 shares at March 31, 2015	530	525
Additional paid-in capital	442,127	426,584
Treasury stock, at cost - 306 shares at December 31, 2015 and 266 shares at March 31, 2015	(5,121)	(3,478)
Accumulated other comprehensive loss, net of tax	(29,974)	(23,412)
Retained earnings	313,376	227,405
Total Stockholders' Equity	720,938	627,624
Total Liabilities and Stockholders' Equity	$ 2,640,999	$ 2,641,967

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2015	Mar. 31, 2015
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (shares)	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (shares)	250,000,000	250,000,000
Common stock, shares issued	53,059,000	52,562,000
Treasury stock, shares	306,000	266,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating Activities
Net income	$ 85,971	$ 54,488
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	17,478	11,967
Gain on sale of asset	0	1,133
Deferred income taxes	31,591	19,517
Amortization of debt origination costs	5,433	5,904
Stock-based compensation costs	7,098	4,919
Loss on extinguishment of debt	451	0
Lease termination costs	0	1,125
(Gain) loss on sale or disposal of property and equipment	(36)	321
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	2,453	2,113
Inventories	(7,114)	14,478
Prepaid expenses and other current assets	5,472	7,598
Accounts payable	(17,553)	(25,452)
Accrued liabilities	5,207	8,297
Net cash provided by operating activities	136,451	104,142
Investing Activities
Purchases of property and equipment	(2,540)	(3,700)
Proceeds from the sale of property and equipment	344	0
Proceeds from sale of business	0	18,500
Proceeds from sale of asset	0	10,000
Proceeds from Insight Pharmaceuticals working capital arbitration settlement	7,237	0
Net cash provided by (used in) investing activities	5,041	(802,857)
Financing Activities
Term loan borrowings	0	720,000
Term loan repayments	(50,000)	(80,000)
Borrowings under revolving credit agreement	15,000	124,600
Repayments under revolving credit agreement	(81,100)	(58,500)
Payments of debt origination costs	(4,211)	(16,072)
Proceeds from exercise of stock options	6,600	3,654
Proceeds from restricted stock exercises	544	57
Excess tax benefits from share-based awards	1,850	1,030
Fair value of shares surrendered as payment of tax withholding	(2,187)	(1,688)
Net cash (used in) provided by financing activities	(113,504)	693,081
Effects of exchange rate changes on cash and cash equivalents	(333)	(746)
Increase (decrease) in cash and cash equivalents	27,655	(6,380)
Cash and cash equivalents - beginning of period	21,318	28,331
Cash and cash equivalents - end of period	48,973	21,951
Interest paid	58,867	49,435
Income taxes paid	9,014	7,135
Insight Pharmaceuticals
Investing Activities
Acquisition of the Hydralyte brand	0	(749,666)
Hydralyte
Investing Activities
Acquisition of the Hydralyte brand	$ 0	$ (77,991)

Business and Basis of Presentat

Business and Basis of Presentation	9 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Nature of Business Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 9 to these Consolidated Financial Statements. Basis of Presentation The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in these Consolidated Financial Statements. In the opinion of management, these Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2016”) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the three and nine months ended December 31, 2015 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2016 . These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015 . Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate. Cash and Cash Equivalents We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at December 31, 2015 are uninsured. Accounts Receivable We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance. Inventories Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method. We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence. Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * * Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Goodwill The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the product group level, which is one level below the operating segment level. Intangible Assets Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Debt Origination Costs We have incurred debt origination costs in connection with the issuance of long-term debt. Certain of these costs were recorded as deferred financing costs within long-term assets and others were recorded as a reduction to our long-term debt. These costs are amortized over the term of the related debt, using the effective interest method for our term loan facility and the straight-line method for our revolving credit facility. Effective April 1, 2015, in accordance with new accounting standards discussed below, we began reporting the costs related to our senior notes and the term loan facility as a reduction of debt. We continue to report the costs associated with our revolving credit facility as a long-term asset. Revenue Recognition Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience. As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of a promotional program, the estimated amounts are adjusted to actual results. Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising. Cost of Sales Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Shipping, warehousing and handling costs were $10.1 million and $29.2 million for the three and nine months ended December 31, 2015 , respectively, and $9.2 million and $26.3 million for the three and nine months ended December 31, 2014 , respectively. Advertising and Promotion Costs Advertising and promotion costs are expensed as incurred. Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees. Stock-based Compensation We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period. Income Taxes Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our tax uncertainties. We are subject to taxation in the United States and various state and foreign jurisdictions. We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income. Earnings Per Share Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, and unvested restricted stock units, are included in the earnings per share calculation to the extent that they are dilutive. Recently Issued Accounting Standards In January 2016, the FASB issued Accounting Standards Update ("ASU") 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . For public business entities, the amendments in this update include the elimination of the requirement to disclose the method(s) and significant assumptions used to estimate fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet, the requirement to use the exit price notion when measuring fair value of financial instruments for disclosure purposes, the requirement to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments, the requirement for separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or accompanying notes to the financial statements, and the amendments clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity's other deferred tax assets. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption of the amendments in this update is not permitted, except that early application by public business entities to financial statements of fiscal years or interim periods that have not yet been issued or, by all other entities, that have not yet been made available for issuance are permitted as of the beginning of the fiscal year of adoption for the following amendment: An entity should present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk if the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. An entity should apply the amendments to this update by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes . The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. For public business entities, the amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In September 2015, the FASB issued ASU 2015-16, Simplifying the Accounting for Measurement-Period Adjustments . The amendments in this update require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. To simplify the accounting for adjustment made to provisional amounts recognized in a business combination, the amendments in this update eliminate the requirement to retrospectively account for those adjustments. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The adoption of ASU 2015-16 is not expected to have a material impact on our Consolidated Financial Statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory . The amendments in this update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards, under which an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs ("ASU 2015-03"). The amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. As permitted by the guidance, we have early adopted these provisions, as of the beginning of our first quarter of 2016. Given the absence of authoritative guidance within ASU 2015-03 for debt issuance costs related to line-of-credit arrangements, in August 2015, the FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements , stating that the SEC staff would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement . As a result, we reclassified $27.4 million of deferred financing costs as of March 31, 2015 from other long-term assets, and such costs are now presented as a direct deduction from the long-term debt liability. In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis . Update 2015-02 amended the process that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. The amendments in this update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-02 is not expected to have a material impact on our Consolidated Financial Statements. In January 2015, the FASB issued ASU 2015-01, Income Statement - Extraordinary and Unusual Items . The amendments in this update eliminate the concept of extraordinary items in Subtopic 225-20, which required entities to consider whether an underlying event or transaction is extraordinary. However, the amendments retain the presentation and disclosure guidance for items that are unusual in nature or occur infrequently. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The adoption of ASU 2015-01 is not expected to have a material impact on our Consolidated Financial Statements. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606 , which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In August 2015, the FASB issued ASU 2015-14, which deferred the effective date of ASU 2014-09 from annual and interim periods beginning after December 15, 2016 to annual and interim periods beginning after December 15, 2017. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity . Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 did not have a material impact on our Consolidated Financial Statements. Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

Acquisitions

Acquisitions	9 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Acquisitions	Acquisitions Acquisition of Insight Pharmaceuticals On September 3, 2014, the Company completed the acquisition of Insight Pharmaceuticals Corporation ("Insight"), a marketer and distributor of feminine care and other OTC healthcare products, for $745.9 million in cash after receiving a return of approximately $7.2 million from escrow related to an arbitrator's ruling. The closing followed the Federal Trade Commission’s (“FTC”) approval of the acquisition and was finalized pursuant to the terms of the purchase agreement announced on April 25, 2014. Pursuant to the Insight purchase agreement, the Company acquired 27 OTC brands sold in North America (including related trademarks, contracts and inventory), which extended the Company's portfolio of OTC brands to include a leading feminine care platform in the United States and Canada anchored by Monistat , the leading brand in OTC yeast infection treatment. The acquisition also added brands to the Company's cough & cold, pain relief, ear care and dermatological platforms. In connection with the FTC's approval of the Insight acquisition, we sold one of the competing brands that we acquired from Insight on the same day as the Insight closing. The Insight brands are primarily included in our North American OTC Healthcare segment. The Insight acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition. We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. During the quarter ended June 30, 2015, we adjusted the fair values of the assets acquired and liabilities assumed by increasing goodwill for certain immaterial items that came to our attention subsequent to the date of acquisition. Additionally, during the quarter ended December 31, 2015, we reduced goodwill, as we received $7.2 million as a result of a finalized arbitration ruling relating to the disputed working capital calculation, as determined under GAAP, as of the date of the Insight acquisition, which is clearly and directly related to the purchase price. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date, after giving effect of the adjustments noted above. (In thousands) September 3, 2014 Cash acquired $ 3,507 Accounts receivable 26,012 Inventories 23,456 Deferred income tax assets - current 1,032 Prepaids and other current assets 1,341 Property, plant and equipment 2,308 Goodwill 96,323 Intangible assets 724,374 Total assets acquired 878,353 Accounts payable 16,079 Accrued expenses 8,539 Deferred income tax liabilities - long term 107,799 Total liabilities assumed 132,417 Total purchase price $ 745,936 Based on this analysis, we allocated $ 599.6 million to indefinite-lived intangible assets and $ 124.8 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 16.2 years. The weighted average remaining life for amortizable intangible assets at December 31, 2015 was 14.8 years. We also recorded goodwill of $ 96.3 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired after the effect of the adjustments described above. Goodwill is not deductible for income tax purposes. The operating results of Insight have been included in our Consolidated Financial Statements beginning September 3, 2014. On September 3, 2014, we sold one of the brands we acquired from the Insight acquisition for $18.5 million , for which we had allocated $17.7 million , $0.6 million and $0.2 million to intangible assets, inventory and property, plant and equipment, respectively. The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results. (In thousands, except per share data) Nine Months Ended December 31, 2014 Revenues $ 593,171 Net income $ 62,688 Earnings per share: Basic $ 1.20 Diluted $ 1.19 Acquisition of the Hydralyte brand On April 30, 2014, we completed the acquisition of the Hydralyte brand in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia, which was funded through a combination of cash on hand and our existing senior secured credit facility. Hydralyte is the leading OTC brand in oral rehydration in Australia and is marketed and sold through our Care Pharmaceuticals Pty Ltd. subsidiary ("Care Pharma"). Hydralyte is available in pharmacies in multiple forms and is indicated for oral rehydration following diarrhea, vomiting, fever, heat and other ailments. Hydralyte is included in our International OTC Healthcare segment. The Hydralyte acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition. We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date. (In thousands) April 30, 2014 Inventories $ 1,970 Property, plant and equipment, net 1,267 Goodwill 1,224 Intangible assets, net 73,580 Total assets acquired 78,041 Accrued expenses 38 Other long-term liabilities 12 Total liabilities assumed 50 Net assets acquired $ 77,991 Based on this analysis, we allocated $73.6 million to non-amortizable intangible assets and no allocation was made to amortizable intangible assets. We also recorded goodwill of $1.2 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes. The pro forma effect of this acquisition on revenues and earnings was not material.

Accounts Receivable

Accounts Receivable	9 Months Ended
	Dec. 31, 2015
Receivables [Abstract]
Accounts Receivable	Accounts Receivable Accounts receivable consist of the following: (In thousands) December 31, March 31, Components of Accounts Receivable Trade accounts receivable $ 94,636 $ 95,411 Other receivables 1,436 2,353 96,072 97,764 Less allowances for discounts, returns and uncollectible accounts (10,987 ) (9,906 ) Accounts receivable, net $ 85,085 $ 87,858

Inventories

Inventories	9 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: (In thousands) December 31, March 31, Components of Inventories Packaging and raw materials $ 8,097 $ 7,588 Finished goods 72,574 66,412 Inventories $ 80,671 $ 74,000 Inventories are carried and depicted above at the lower of cost or market value, which includes a reduction in inventory values of $2.6 million and $4.1 million at December 31, 2015 and March 31, 2015 , respectively, related to obsolete and slow-moving inventory.

Property and Equipment

Property and Equipment	9 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consist of the following: (In thousands) December 31, March 31, Components of Property and Equipment Machinery $ 4,085 $ 4,743 Computer equipment 13,843 11,339 Furniture and fixtures 2,406 2,484 Leasehold improvements 7,371 7,134 27,705 25,700 Accumulated depreciation (15,403 ) (11,956 ) Property and equipment, net $ 12,302 $ 13,744 We recorded depreciation expense of $1.2 million and $3.7 million for the three and nine months ended December 31, 2015, respectively, and $1.0 million and $2.6 million for the three and nine months ended December 31, 2014, respectively.

Goodwill

Goodwill	9 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC Healthcare International OTC Healthcare Household Cleaning Consolidated Balance — March 31, 2015 $ 263,411 $ 20,440 $ 6,800 $ 290,651 Adjustments (6,932 ) — — (6,932 ) Effects of foreign currency exchange rates — (1,040 ) — (1,040 ) Balance — December 31, 2015 $ 256,479 $ 19,400 $ 6,800 $ 282,679 As discussed in Note 2, we completed two acquisitions during the year ended March 31, 2015. On September 3, 2014, we completed the acquisition of Insight and recorded goodwill of $96.3 million , reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of net assets acquired, after giving effect to the following adjustments. During the quarter ended June 30, 2015, we increased goodwill by $0.3 million for certain immaterial items. During the quarter ended December 31, 2015, we decreased goodwill by $7.2 million , as we received that amount from escrow pursuant to an arbitrator's ruling in December 2015 related to a disputed working capital calculation, as determined under GAAP, associated with the Insight acquisition, which is clearly and directly related to the purchase price. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and recorded goodwill of $1.2 million , reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of the net assets acquired. As further discussed in Note 7, in December 2014, we completed a transaction to sell rights to use of the Comet brand in certain Eastern European countries to a third-party licensee. As a result, we recorded a gain on sale of $1.3 million and reduced the carrying value of our intangible assets and goodwill. Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. On an annual basis during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment. We utilize the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test and the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. We also considered our market capitalization at February 28, 2015 , which was the date of our annual review, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future. At February 28, 2015 , during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in fiscal 2015. As of December 31, 2015, there have been no triggering events that would indicate potential impairment of goodwill.

Intangible Assets

Intangible Assets	9 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets A reconciliation of the activity affecting intangible assets is as follows: (In thousands) Indefinite Lived Trademarks Finite Lived Trademarks Totals Gross Carrying Amounts Balance — March 31, 2015 $ 1,873,404 $ 358,066 $ 2,231,470 Effects of foreign currency exchange rates (4,383 ) (70 ) (4,453 ) Balance — December 31, 2015 1,869,021 357,996 2,227,017 Accumulated Amortization Balance — March 31, 2015 — 96,770 96,770 Additions — 13,745 13,745 Effects of foreign currency exchange rates — (9 ) (9 ) Balance — December 31, 2015 — 110,506 110,506 Intangible assets, net - December 31, 2015 $ 1,869,021 $ 247,490 $ 2,116,511 Intangible Assets, net by Reportable Segment: North American OTC Healthcare $ 1,676,991 $ 223,272 $ 1,900,263 International OTC Healthcare 81,758 1,104 82,862 Household Cleaning 110,272 23,114 133,386 Intangible assets, net - December 31, 2015 $ 1,869,021 $ 247,490 $ 2,116,511 As discussed in Note 2, we completed two acquisitions during the year ended March 31, 2015. On September 3, 2014, we completed the acquisition of Insight and allocated $724.4 million to intangible assets based on our preliminary analysis. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and allocated $73.6 million to intangible assets based on our preliminary analysis. Furthermore, on September 3, 2014, we sold one of the brands that we acquired from Insight, for which we had allocated $17.7 million to intangible assets. Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value. On an annual basis during the fourth fiscal quarter, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to intangible assets and tests for impairment. We utilize the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test and the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. We also considered our market capitalization at February 28, 2015 , which was the date of our annual review, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future. Although we experienced declines in revenues in Pediacare and in certain other brands in the past, we continue to believe that the fair values of our brands exceed their carrying values. However, sustained or significant future declines in revenue, profitability, lost distribution, other adverse changes in expected operating results, and/or unfavorable changes in other economic factors used to estimate fair value of certain brands could indicate that the fair value no longer exceeds carrying value in which case a non-cash impairment charge may be recorded in future periods. The weighted average remaining life for finite-lived intangible assets at December 31, 2015 was approximately 13.9 years, and the amortization expense for the three and nine months ended December 31, 2015 was $4.8 million and $13.7 million , respectively. At December 31, 2015 , finite-lived intangible assets are being amortized over a period of 10 to 30 years, and the associated amortization expense is expected to be as follows: (In thousands) Year Ending March 31, Amount 2016 (Remaining three months ending March 31, 2016) $ 4,466 2017 17,863 2018 17,863 2019 17,863 2020 17,863 Thereafter 171,572 $ 247,490 Sale of asset Historically, we received royalty income from the licensing of the name of certain of our brands in geographic areas or markets in which we do not directly compete. We have had a royalty agreement for our Comet brand for several years, which included an option on behalf of the licensee to purchase the rights in certain geographic areas and markets in perpetuity. In December 2014, we amended the agreement to allow the licensee to buy out a portion of the agreement early, but retaining the remaining stream of royalty payments. In December 2014, in connection with this amendment, we sold rights to use of the Comet brand in certain Eastern European countries to a third-party licensee and received $10.0 million as a partial early buyout. As a result, we recorded a gain on sale of $1.3 million , and reduced the carrying value of our intangible assets and goodwill. The licensee will continue to make quarterly payments at least through June 30, 2016 of approximately $1.0 million . The licensee has the option to purchase the remaining territories and markets, as defined in the agreement, at any time after July 1, 2016.

Other Accrued Liabilities

Other Accrued Liabilities	9 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consist of the following: (In thousands) December 31, March 31, Accrued marketing costs $ 24,757 $ 16,903 Accrued compensation costs 6,837 8,840 Accrued broker commissions 1,231 1,134 Income taxes payable 3,456 2,642 Accrued professional fees 2,229 2,769 Deferred rent 825 1,021 Accrued production costs 5,303 5,610 Accrued lease termination costs 544 669 Other accrued liabilities 3,641 1,360 $ 48,823 $ 40,948

Long-Term Debt

Long-Term Debt	9 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt 2012 Senior Notes: On January 31, 2012, Prestige Brands, Inc. (the "Borrower") issued $250.0 million of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower may earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2012 Senior Notes. 2012 Term Loan and 2012 ABL Revolver: On January 31, 2012, the Borrower also entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a 7 -year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a 5 -year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25% . The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million . In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. On February 21, 2013, the Borrower entered into Amendment No. 1 (the "Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loans"). The interest rate on the Term B-1 Loans under the Term Loan Amendment No. 1 was based, at the Borrower's option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00% , or an alternate base rate, with a floor of 2.00% , plus a margin. The new Term B-1 Loans mature on the same date as the Term B Loans' original maturity date. In addition, Term Loan Amendment No. 1 provided the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with Term Loan Amendment No. 1, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt. On September 3, 2014, the Borrower entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provided for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loans") in an aggregate principal amount of $720.0 million , (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on (x) the Term B-1 Loans that was based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00% , or an alternate base rate, with a floor of 2.00% , plus a margin, and (y) the Term B-2 Loans that was based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00% , or an alternate base rate, with a floor of 2.00% , plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio). On May 8, 2015, the Borrower entered into Amendment No. 3 (the "Term Loan Amendment No. 3") to the 2012 Term Loan. Term Loan Amendment No. 3 provides for (i) the creation of a new class of Term B-3 Loans under the 2012 Term Loan (the "Term B-3 Loans") in an aggregate principal amount of $852.5 million , which combined the outstanding balances of the Term B-1 Loans of $207.5 million and the Term B-2 Loans of $645.0 million , (ii) increased flexibility under the credit agreement governing the 2012 Term Loan, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on the Term B-3 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 0.75% , or an alternate base rate, with a floor of 1.75% , plus a margin. The maturity date of the Term B-3 Loans remains the same as the Term B-2 Loans' original maturity date of September 3, 2021. The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50% , (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 1.75% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, with a floor of 0.75% . For the nine months ended December 31, 2015 , the average interest rate on the 2012 Term Loan was 4.5% . Under the 2012 Term Loan, we were originally required to make quarterly payments each equal to 0.25% of the original principal amount of the 2012 Term Loan, with the balance expected to be due on the seventh anniversary of the closing date. However, since we entered into Term Loan Amendment No. 3, we are required to make quarterly payments each equal to 0.25% of the aggregate principal amount of $852.5 million . Since we have previously made optional payments that exceeded a significant portion of our required quarterly payments, we will not be required to make another payment until the fiscal year ending March 31, 2019. On September 3, 2014, the Borrower entered into Amendment No. 3 (“ABL Amendment No. 3”) to the 2012 ABL Revolver. ABL Amendment No. 3 provided for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50% , (b) the prime rate of Citibank, N.A., or (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. On June 9, 2015, the Borrower entered into Amendment No. 4 (“ABL Amendment No. 4”) to the 2012 ABL Revolver. ABL Amendment No. 4 provides for (i) a $35.0 million increase in the accordion feature under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief and (iii) extended the maturity date of the 2012 ABL Revolver to June 9, 2020, which is five years from the effective date. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the nine months ended December 31, 2015 , the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 2.1% . 2013 Senior Notes: On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $7.2 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes. Redemptions and Restrictions: At any time prior to February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a "make-whole premium" calculated as set forth in the indenture governing the 2012 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at redemption prices set forth in the indenture governing the 2012 Senior Notes. In addition, at any time prior to February 1, 2015, we could have redeemed up to 35% of the aggregate principal amount of the 2012 Senior Notes at a redemption price equal to 108.125% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions were met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2012 Senior Notes, the Borrower will be required to make an offer to purchase the 2012 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2012 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. At any time prior to December 15, 2016, we may redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the indenture governing the 2013 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after December 15, 2016, we may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we may redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2013 Senior Notes, the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. The indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes. At December 31, 2015 , we were in compliance with the covenants under our long-term indebtedness. Effective April 1, 2015, the Company elected to change its method of presentation relating to debt issuance costs in accordance with ASU 2015-03. Prior to 2016, the Company's policy was to present these costs in other-long term assets on the balance sheet, net of accumulated amortization. Beginning in 2016, the Company has presented these fees as a direct deduction to the related long-term debt. As a result, we reclassified $27.4 million of deferred financing costs as of March 31, 2015 from other long-term assets, and such costs are now presented as a direct deduction from the long-term debt liability. At December 31, 2015, we had an aggregate of $30.5 million of unamortized debt costs, the total of which is comprised of $7.6 million related to the 2012 Senior Notes, $5.7 million related to the 2013 Senior Notes and $17.2 million related to the 2012 Term Loan. As of December 31, 2015, there were no outstanding borrowings on the 2012 ABL Revolver and we had a borrowing capacity of $115.4 million . Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) December 31, March 31, 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021. $ 400,000 $ 400,000 2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020. 250,000 250,000 2012 Term B-3 Loans bearing interest at the Borrower's option at either a base rate with a floor of 1.75% plus applicable margin or LIBOR with a floor of 0.75% plus applicable margin, due on September 3, 2021. 827,500 877,500 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on June 9, 2020. — 66,100 Total long-term debt (including current portion) 1,477,500 1,593,600 Current portion of long-term debt — — Long-term debt 1,477,500 1,593,600 Less: unamortized debt costs (30,468 ) (32,327 ) Long-term debt, net $ 1,447,032 $ 1,561,273 As of December 31, 2015, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows: (In thousands) Year Ending March 31, Amount 2016 (remaining three months ending March 31, 2016) $ — 2017 — 2018 — 2019 6,969 2020 258,525 Thereafter 1,212,006 $ 1,477,500

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. The Fair Value Measurements and Disclosures topic of the FASB ASC 820 requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2013 Senior Notes, the 2012 Senior Notes, the Term B-3 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. At December 31, 2015 and March 31, 2015 , we did not have any assets or liabilities measured in Level 1 or 3. During the periods presented, there were no transfers of assets or liabilities between Levels 1, 2 and 3. At December 31, 2015 and March 31, 2015 , the carrying value of our 2013 Senior Notes was $400.0 million . The fair value of our 2013 Senior Notes was $384.0 million and $405.0 million at December 31, 2015 and March 31, 2015 , respectively. At December 31, 2015 and March 31, 2015 , the carrying value of our 2012 Senior Notes was $250.0 million . The fair value of our 2012 Senior Notes was $257.5 million and $268.1 million at December 31, 2015 and March 31, 2015 , respectively. At December 31, 2015 and March 31, 2015 , the carrying value of the Term B-3 Loans was $827.5 million and $877.5 million , respectively. The fair value of the Term B-3 Loans was $822.3 million and $880.5 million at December 31, 2015 and March 31, 2015 , respectively. At December 31, 2015 and March 31, 2015 , the carrying value of the 2012 ABL Revolver was $0.0 million and $66.1 million , respectively. The fair value of the 2012 ABL revolver was $0.0 million and $65.7 million at December 31, 2015 and March 31, 2015, respectively.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through December 31, 2015 . During the three and nine months ended December 31, 2015 , we repurchased 0 shares and 39,429 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. During the three and nine months ended December 31, 2014, we repurchased 781 shares and 48,445 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the nine months ended December 31, 2015 and 2014 were at an average price of $41.66 and $33.66 , respectively. All of the repurchased shares have been recorded as treasury stock.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The table below presents accumulated other comprehensive loss (“AOCI”), which affects equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners. AOCI consisted of the following at December 31, 2015 and March 31, 2015 : December 31, March 31, (In thousands) 2015 2015 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (29,974 ) $ (23,412 ) Accumulated other comprehensive loss, net of tax $ (29,974 ) $ (23,412 )

Earnings Per Share

Earnings Per Share	9 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2015 2014 2015 2014 Numerator Net income $ 27,995 $ 21,293 $ 85,971 $ 54,488 Denominator Denominator for basic earnings per share — weighted average shares outstanding 52,824 52,278 52,727 52,110 Dilutive effect of unvested restricted stock units and options issued to employees and directors 379 452 379 512 Denominator for diluted earnings per share 53,203 52,730 53,106 52,622 Earnings per Common Share: Basic net earnings per share $ 0.53 $ 0.41 $ 1.63 $ 1.05 Diluted net earnings per share $ 0.53 $ 0.40 $ 1.62 $ 1.04 For the three months ended December 31, 2015 and 2014, there were 0.2 million and 0.3 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the nine months ended December 31, 2015 and 2014, there were less than 0.1 million and 0.3 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, the stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, increased the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any 12-month period from 1.0 million to 2.5 million shares, and extended the term of the Plan by ten years to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan. During the three and nine months ended December 31, 2015 , pre-tax share-based compensation costs charged against income were $2.1 million and $7.1 million , respectively, and the related income tax benefit recognized was $0.7 million and $2.5 million , respectively. During the three and nine months ended December 31, 2014 , pre-tax share-based compensation costs charged against income were $1.5 million and $4.9 million , respectively, and the related income tax benefit recognized was $0.6 million and $1.8 million , respectively. On April 22, 2015, we announced that Matthew M. Mannelly, our President and Chief Executive Officer and member of the Board of Directors, would retire effective June 1, 2015. In conjunction with his retirement, the Board of Directors accelerated the vesting of his previously unvested restricted stock units and stock options, and we recorded additional compensation expense of approximately $0.8 million associated with this acceleration. Effective June 1, 2015, the Board of Directors appointed Ron M. Lombardi, our then current Chief Financial Officer, to succeed Mr. Mannelly as President and Chief Executive Officer and as a member of the Board of Directors. In connection with his appointment, Mr. Lombardi was granted 57,924 restricted stock units on April 22, 2015. On October 28, 2015, we announced that David S. Marberger has been appointed as Chief Financial Officer of the Company, effective November 10, 2015. In connection with Mr. Marberger’s appointment as Chief Financial Officer, on October 28, 2015, the Company entered into an employment agreement with Mr. Marberger, which sets forth the terms of his compensation as approved by the Compensation Committee of the Board of Directors. In accordance with the terms of his employment agreement, on October 28, 2015, the Company granted to Mr. Marberger, 6,612 shares of restricted stock units and stock options to acquire 8,079 shares of our common stock under the Plan. The restricted stock units vest in their entirety on the three -year anniversary of the date of grant. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $50.42 per share, which is equal to the closing price of our common stock on the date of grant. On May 11, 2015, the Compensation Committee of our Board of Directors (the "Compensation Committee") granted 185,904 restricted stock units and stock options to acquire 186,302 shares of our common stock to certain executive officers and employees under the Plan. Of those grants, 163,404 restricted stock units vest in their entirety on the three -year anniversary of the date of grant and 22,500 restricted stock units vest 33.3% per year over three years. Upon vesting, the units will be settled in shares of our common stock. The stock options vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $41.44 per share, which is equal to the closing price of our common stock on the date of grant. On July 1, 2015, the Compensation Committee granted 2,841 restricted stock units, which vest on the three -year anniversary of the date of grant, and stock options to acquire 13,861 shares of our common stock to certain employees under the Plan. The stock options vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $46.58 per share, which is equal to the closing price of our common stock on the date of grant. Restricted Shares Restricted shares granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The restricted share awards provide for accelerated vesting if there is a change of control, as defined in the Plan. The restricted stock units granted to employees generally vest in their entirety on the three -year anniversary of the date of the grant. Termination of employment prior to vesting will result in forfeiture of the restricted stock units, unless otherwise accelerated by the Compensation Committee. The restricted stock units granted to directors vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, with the settlement in common stock to occur on the earliest of the director's death, disability or six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. Upon vesting, the units will be settled in shares of our common stock. Each of our six independent members of the Board of Directors received a grant of 2,075 restricted stock units on August 4, 2015 under the Plan. Additionally, on May 11, 2015, the Compensation Committee granted 362 restricted stock units to a newly appointed Board member. The restricted stock units vest on the one year anniversary of the date of grant and will be settled by delivery to the director of one share of common stock of the Company for each vested restricted stock unit promptly following the earliest of the director's (i) death, (ii) disability or (iii) the six -month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. The fair value of the restricted stock units is determined using the closing price of our common stock on the date of the grant. The weighted-average grant-date fair value during the nine months ended December 31, 2015 and 2014 was $42.41 and $33.30 , respectively. A summary of the Company's restricted shares granted under the Plan is presented below: Restricted Shares Shares (in thousands) Weighted- Average Grant-Date Fair Value Nine months ended December 31, 2014 Vested and nonvested at March 31, 2014 437.5 $ 16.76 Granted 104.4 33.30 Vested and issued (122.8 ) 13.62 Forfeited (21.3 ) 20.77 Vested and nonvested at December 31, 2014 397.8 21.86 Vested at December 31, 2014 76.6 11.62 Nine months ended December 31, 2015 Vested and nonvested at March 31, 2015 362.3 $ 22.74 Granted 266.1 42.41 Vested and issued (153.6 ) 18.16 Forfeited (1.4 ) 33.50 Vested and nonvested at December 31, 2015 473.4 35.25 Vested at December 31, 2015 69.8 14.76 Options The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination of employment, subject to the terms in the Plan. The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management's estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options. The weighted-average grant-date fair values of the options granted during the nine months ended December 31, 2015 and 2014 were $17.24 and $15.93 , respectively. Nine Months Ended December 31, 2015 2014 Expected volatility 40.2 % 47.3 % Expected dividends $ — $ — Expected term in years 6.0 6.0 Risk-free rate 1.7 % 2.2 % A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Nine months ended December 31, 2014: Outstanding at March 31, 2014 994.9 $ 15.24 Granted 307.5 33.50 Exercised (363.4 ) 10.05 Forfeited or expired (47.5 ) 25.76 Outstanding at December 31, 2014 891.5 23.09 7.9 $ 10,368 Exercisable at December 31, 2014 335.1 15.01 6.7 6,604 Nine months ended December 31, 2015: Outstanding at March 31, 2015 871.2 $ 23.40 Granted 208.2 42.13 Exercised (336.9 ) 18.99 Forfeited or expired (2.1 ) 38.21 Outstanding at December 31, 2015 740.4 30.63 7.9 $ 15,325 Exercisable at December 31, 2015 313.5 21.68 6.7 9,341 The aggregate intrinsic value of options exercised in the nine months ended December 31, 2015 was $8.4 million . At December 31, 2015 , there were $11.6 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 1.1 years. The total fair value of options and restricted shares vested during the nine months ended December 31, 2015 and 2014 was $6.6 million and $4.3 million , respectively. For the nine months ended December 31, 2015 and 2014, cash received from the exercise of stock options was $6.6 million and $3.7 million , respectively, and we realized $2.1 million and $1.9 million , respectively, in tax benefits from the tax deductions resulting from these option exercises. At December 31, 2015 , there were 2.6 million shares available for issuance under the Plan.

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates used in the calculation of income taxes were 35.2% and 36.5% for the three months ended December 31, 2015 and 2014, respectively. The effective tax rates used in the calculation of income taxes were 35.2% and 39.5% for the nine months ended December 31, 2015 and 2014, respectively. The decrease in the effective tax rate for the three and nine months ended December 31, 2015 was primarily due to the impact of certain non-deductible items related to acquisitions in the prior year period and to favorable tax deductions related to stock options, equity awards and to certain foreign tax credits realized in the current period. At December 31, 2015 , 100% owned subsidiaries of the Company had net operating loss carryforwards of approximately $36.2 million , which may be used to offset future taxable income of the consolidated group and which begin to expire in 2020. The net operating loss carryforwards are subject to an annual limitation as to usage of approximately $33.6 million pursuant to Internal Revenue Code Section 382. The Company expects to utilize all of the net operating loss carryforwards before they expire. We had a net increase of $0.7 million in our uncertain tax liability during the nine months ended December 31, 2015. Therefore, the balance in our uncertain tax liability was $4.1 million at December 31, 2015 and $3.4 million March 31, 2015. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in any of the periods presented.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not be material to our financial condition or results of operations. Lease Commitments We have operating leases for office facilities and equipment in New York, Wyoming, and other locations, which expire at various dates through fiscal 2021. These amounts have been included in the table below. The following summarizes future minimum lease payments for our operating leases as of December 31, 2015 (a) : (In thousands) Year Ending March 31, Facilities Equipment Total 2016 (Remaining three months ending March 31, 2016) $ 455 $ 47 $ 502 2017 1,923 77 2,000 2018 1,934 — 1,934 2019 1,926 — 1,926 2020 1,757 — 1,757 Thereafter 817 — 817 $ 8,812 $ 124 $ 8,936 (a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.2 million due in the future under noncancelable subleases. The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals: (In thousands) December 31, 2015 March 31, 2015 Minimum lease payments $ 8,936 $ 9,957 Less: Sublease rentals (1,224 ) (1,401 ) $ 7,712 $ 8,556 Rent expense for the three and nine months ended December 31, 2015 was $0.4 million and $1.2 million , respectively. Rent expense for the three and nine months ended December 31, 2014 was $0.4 million and $1.2 million , respectively. Purchase Commitments Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products. Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement. (In thousands) Year Ending March 31, Amount 2016 (Remaining three months ending March 31, 2016) 266 2017 1,044 2018 1,013 2019 982 2020 560 Thereafter — $ 3,865

Concentrations of Risk

Concentrations of Risk	9 Months Ended
	Dec. 31, 2015
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products. We sell our products to mass merchandisers, food and drug stores, and convenience, dollar and club stores. During the three and nine months ended December 31, 2015 , approximately 41.0% and 42.2% , respectively, of our total revenues were derived from our five top selling brands. During the three and nine months ended December 31, 2014 , approximately 44.3% and 41.9% , respectively, of our total revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 20.2% and 19.9% , respectively, of our gross revenues for the three and nine months ended December 31, 2015 , and approximately 16.5% and 17.4% , respectively, of our gross revenues for the three and nine months ended December 31, 2014 . Our next largest customer accounted for approximately 9.5% and 9.6% , respectively, of gross revenues for the three and nine months ended December 31, 2015. At December 31, 2015 , approximately 20.9% of accounts receivable were owed by Walmart. We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri. A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center and inventory levels. As a result, any such disruption could have a material adverse effect on our business, sales and profitability. At December 31, 2015 , we had relationships with 101 third-party manufacturers. Of those, we had long-term contracts with 47 manufacturers that produced items that accounted for approximately 79.8% of gross sales for the nine months ended December 31, 2015 . At December 31, 2014 , we had relationships with 96 third-party manufacturers. Of those, we had long-term contracts with 44 manufacturers that produced items that accounted for approximately 80.1% of gross sales for the nine months ended December 31, 2014 . The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results from operations. Although we are in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach an agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

Business Segments	9 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Business Segments	Business Segments Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare, (ii) International OTC Healthcare and (iii) Household Cleaning. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses. The tables below summarize information about our reportable segments. Three Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues* $ 165,278 $ 13,812 $ 20,623 $ 199,713 Elimination of intersegment revenues (228 ) — — (228 ) Third-party segment revenues 165,050 13,812 20,623 199,485 Other revenues* — 9 701 710 Total segment revenues 165,050 13,821 21,324 200,195 Cost of sales 62,654 4,965 15,792 83,411 Gross profit 102,396 8,856 5,532 116,784 Advertising and promotion 26,472 2,838 625 29,935 Contribution margin $ 75,924 $ 6,018 $ 4,907 86,849 Other operating expenses 24,206 Operating income 62,643 Other expense 19,462 Income before income taxes 43,181 Provision for income taxes 15,186 Net income $ 27,995 Nine Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues* $ 489,224 $ 43,254 $ 65,984 $ 598,462 Elimination of intersegment revenues (2,428 ) — — (2,428 ) Third-party segment revenues 486,796 43,254 65,984 596,034 Other revenues* 14 41 2,303 2,358 Total segment revenues 486,810 43,295 68,287 598,392 Cost of sales 182,279 16,347 50,806 249,432 Gross profit 304,531 26,948 17,481 348,960 Advertising and promotion 74,107 8,338 1,805 84,250 Contribution margin $ 230,424 $ 18,610 $ 15,676 264,710 Other operating expenses 69,664 Operating income 195,046 Other expense 62,464 Income before income taxes 132,582 Provision for income taxes 46,611 Net income $ 85,971 Three Months Ended December 31, 2014 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues* $ 162,163 $ 15,563 $ 20,218 $ 197,944 Elimination of intersegment revenues (1,509 ) — — (1,509 ) Third-party segment revenues 160,654 15,563 20,218 196,435 Other revenues 151 4 1,016 1,171 Total segment revenues 160,805 15,567 21,234 197,606 Cost of sales 63,479 6,247 16,135 85,861 Gross profit 97,326 9,320 5,099 111,745 Advertising and promotion 26,779 2,776 589 30,144 Contribution margin $ 70,547 $ 6,544 $ 4,510 81,601 Other operating expenses 24,608 Operating income 56,993 Other expense 23,459 Income before income taxes 33,534 Provision for income taxes 12,241 Net income $ 21,293 Nine Months Ended December 31, 2014 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues* $ 412,703 $ 45,157 $ 66,057 $ 523,917 Elimination of intersegment revenues (2,936 ) — — (2,936 ) Third-party segment revenues 409,767 45,157 66,057 520,981 Other revenues 478 62 3,056 3,596 Total segment revenues 410,245 45,219 69,113 524,577 Cost of sales 158,005 17,926 52,493 228,424 Gross profit 252,240 27,293 16,620 296,153 Advertising and promotion 64,573 8,151 1,560 74,284 Contribution margin $ 187,667 $ 19,142 $ 15,060 221,869 Other operating expenses 75,555 Operating income 146,314 Other expense 56,305 Income before income taxes 90,009 Provision for income taxes 35,521 Net income $ 54,488 * Certain immaterial amounts relating to intersegment revenues and other revenues were reclassified between the International OTC Healthcare segment and the North American OTC Healthcare segment. There were no changes to the consolidated financial statements for any periods presented. The tables below summarize information about our segment revenues from similar product groups. Three Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 30,454 $ 450 $ — $ 30,904 Cough & Cold 30,466 3,696 — 34,162 Women's Health 33,521 877 — 34,398 Gastrointestinal 17,401 5,517 — 22,918 Eye & Ear Care 21,927 2,622 — 24,549 Dermatologicals 19,734 524 — 20,258 Oral Care 9,996 126 — 10,122 Other OTC 1,551 9 — 1,560 Household Cleaning — — 21,324 21,324 Total segment revenues $ 165,050 $ 13,821 $ 21,324 $ 200,195 Nine Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 86,996 $ 1,668 $ — $ 88,664 Cough & Cold 74,661 12,968 — 87,629 Women's Health 100,036 2,381 — 102,417 Gastrointestinal 56,782 14,667 — 71,449 Eye & Ear Care 71,137 9,415 — 80,552 Dermatologicals 63,026 1,669 — 64,695 Oral Care 29,706 509 — 30,215 Other OTC 4,466 18 — 4,484 Household Cleaning — — 68,287 68,287 Total segment revenues $ 486,810 $ 43,295 $ 68,287 $ 598,392 Three Months Ended December 31, 2014 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 28,187 $ 657 $ — $ 28,844 Cough & Cold 31,927 3,831 — 35,758 Women's Health 31,364 589 — 31,953 Gastrointestinal 17,365 6,668 — 24,033 Eye & Ear Care 20,528 3,069 — 23,597 Dermatologicals 17,663 570 — 18,233 Oral Care 12,300 172 — 12,472 Other OTC 1,471 11 — 1,482 Household Cleaning — — 21,234 21,234 Total segment revenues $ 160,805 $ 15,567 $ 21,234 $ 197,606 Nine Months Ended December 31, 2014 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 82,290 $ 2,114 $ — $ 84,404 Cough & Cold 76,741 14,090 — 90,831 Women's Health 40,851 1,765 — 42,616 Gastrointestinal 58,899 14,764 — 73,663 Eye & Ear Care 64,086 10,311 — 74,397 Dermatologicals 47,383 1,799 — 49,182 Oral Care 35,421 361 — 35,782 Other OTC 4,574 15 — 4,589 Household Cleaning — — 69,113 69,113 Total segment revenues $ 410,245 $ 45,219 $ 69,113 $ 524,577 During the three months ended December 31, 2015 and 2014, approximately 87.8% and 85.9% , respectively, of our total segment revenues were from customers in the United States. During the nine months ended December 31, 2015 and 2014, approximately 86.9% and 84.4% , respectively, of our total segment revenues were from customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented. During the three months ended December 31, 2015, our Canada and Australia sales accounted for approximately 5.0% and 5.0% , respectively, of our total segment revenues, while during the three months ended December 31, 2014, approximately 5.1% and 7.2% , respectively, of our total segment revenues were attributable to sales to Canada and Australia. During the nine months ended December 31, 2015, our Canada and Australia sales accounted for approximately 5.2% and 5.9% , respectively, of our total segment revenues, while during the nine months ended December 31, 2014, approximately 6.1% and 7.5% , respectively, of our total segment revenues were attributable to sales to Canada and Australia. At December 31, 2015 , approximately 95.7% of our consolidated goodwill and intangible assets were located in the United States and approximately 4.3% were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: (In thousands) North American OTC International OTC Household Cleaning Consolidated Goodwill $ 256,479 $ 19,400 $ 6,800 $ 282,679 Intangible assets Indefinite-lived 1,676,991 81,758 110,272 1,869,021 Finite-lived 223,272 1,104 23,114 247,490 Intangible assets, net 1,900,263 82,862 133,386 2,116,511 Total $ 2,156,742 $ 102,262 $ 140,186 $ 2,399,190

Condensed Consolidating Financi

Condensed Consolidating Financial Statements	9 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Financial Statements	Condensed Consolidating Financial Statements As described in Note 9, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, has fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2013 Senior Notes and the 2012 Senior Notes, including the obligation to pay principal and interest with respect to the 2013 Senior Notes and the 2012 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2013 Senior Notes and the 2012 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, Blacksmith Brands, Inc., Insight Pharmaceuticals Corporation, Insight Pharmaceuticals, LLC and Practical Health Products, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2013 Senior Notes and the 2012 Senior Notes. Although holders of the 2013 Senior Notes and the 2012 Senior Notes will be direct creditors of the guarantors of the 2013 Senior Notes and the 2012 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2013 Senior Notes or the 2012 Senior Notes, and such subsidiaries will not be obligated with respect to the 2013 Senior Notes or the 2012 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2013 Senior Notes and the 2012 Senior Notes. Presented below are supplemental Condensed Consolidating Balance Sheets as of December 31, 2015 and March 31, 2015 , Condensed Consolidating Statements of Income and Comprehensive Income for the three and nine months ended December 31, 2015 and 2014 , and Condensed Consolidating Statements of Cash Flows for the nine months ended December 31, 2015 and 2014 . Such consolidating information includes separate columns for: a) Prestige Brands Holdings, Inc., the parent, b) Prestige Brands, Inc., the Issuer or the Borrower, c) Combined Subsidiary Guarantors, d) Combined Non-Guarantor Subsidiaries, and e) Elimination entries necessary to consolidate the Company and all of its subsidiaries. The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q. Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 27,598 $ 159,783 $ 12,332 $ (228 ) $ 199,485 Other revenues — 98 700 356 (444 ) 710 Total revenues — 27,696 160,483 12,688 (672 ) 200,195 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 11,796 68,148 4,448 (981 ) 83,411 Gross profit — 15,900 92,335 8,240 309 116,784 Operating Expenses Advertising and promotion — 1,881 25,251 2,803 — 29,935 General and administrative 1,370 1,789 13,463 1,513 — 18,135 Depreciation and amortization 1,013 151 4,794 113 — 6,071 Total operating expenses 2,383 3,821 43,508 4,429 — 54,141 Operating income (loss) (2,383 ) 12,079 48,827 3,811 309 62,643 Other (income) expense Interest income (12,141 ) (21,569 ) (1,124 ) (128 ) 34,931 (31 ) Interest expense 8,602 19,443 25,255 1,124 (34,931 ) 19,493 Equity in (income) loss of subsidiaries (27,711 ) (15,898 ) (2,033 ) — 45,642 — Total other (income) expense (31,250 ) (18,024 ) 22,098 996 45,642 19,462 Income (loss) before income taxes 28,867 30,103 26,729 2,815 (45,333 ) 43,181 Provision for income taxes 872 4,950 8,582 782 — 15,186 Net income (loss) $ 27,995 $ 25,153 $ 18,147 $ 2,033 $ (45,333 ) $ 27,995 Comprehensive income, net of tax: Currency translation adjustments 4,922 4,922 4,922 4,922 (14,766 ) 4,922 Total other comprehensive income (loss) 4,922 4,922 4,922 4,922 (14,766 ) 4,922 Comprehensive income (loss) $ 32,917 $ 30,075 $ 23,069 $ 6,955 $ (60,099 ) $ 32,917 Condensed Consolidating Statements of Income and Comprehensive Income Nine Months Ended December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 83,438 $ 477,079 $ 37,945 $ (2,428 ) $ 596,034 Other revenues — 273 2,317 1,397 (1,629 ) 2,358 Total revenues — 83,711 479,396 39,342 (4,057 ) 598,392 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 33,105 206,646 13,808 (4,127 ) 249,432 Gross profit — 50,606 272,750 25,534 70 348,960 Operating Expenses Advertising and promotion — 7,602 68,412 8,236 — 84,250 General and administrative 3,884 5,644 38,326 4,332 — 52,186 Depreciation and amortization 3,032 444 13,686 316 — 17,478 Total operating expenses 6,916 13,690 120,424 12,884 — 153,914 Operating income (loss) (6,916 ) 36,916 152,326 12,650 70 195,046 Other (income) expense Interest income (36,351 ) (64,584 ) (3,513 ) (366 ) 104,723 (91 ) Interest expense 26,056 61,654 75,604 3,513 (104,723 ) 62,104 Loss on extinguishment of debt — 451 — — — 451 Equity in (income) loss of subsidiaries (84,458 ) (52,599 ) (6,868 ) — 143,925 — Total other (income) expense (94,753 ) (55,078 ) 65,223 3,147 143,925 62,464 Income (loss) before income taxes 87,837 91,994 87,103 9,503 (143,855 ) 132,582 Provision for income taxes 1,866 13,867 28,243 2,635 — 46,611 Net income (loss) $ 85,971 $ 78,127 $ 58,860 $ 6,868 $ (143,855 ) $ 85,971 Comprehensive income, net of tax: Currency translation adjustments (6,562 ) (6,562 ) (6,562 ) (6,562 ) 19,686 (6,562 ) Total other comprehensive income (loss) (6,562 ) (6,562 ) (6,562 ) (6,562 ) 19,686 (6,562 ) Comprehensive income (loss) $ 79,409 $ 71,565 $ 52,298 $ 306 $ (124,169 ) $ 79,409 Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended December 31, 2014 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 27,937 $ 155,733 $ 14,273 $ (1,508 ) $ 196,435 Other revenues — 83 1,166 266 (344 ) 1,171 Total revenues — 28,020 156,899 14,539 (1,852 ) 197,606 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 10,296 71,891 5,208 (1,534 ) 85,861 Gross profit — 17,724 85,008 9,331 (318 ) 111,745 Operating Expenses Advertising and promotion — 2,175 25,202 2,767 — 30,144 General and administrative 1,408 1,879 13,760 2,407 — 19,454 Depreciation and amortization 869 156 3,864 265 — 5,154 Total operating expenses 2,277 4,210 42,826 5,439 — 54,752 Operating income (loss) (2,277 ) 13,514 42,182 3,892 (318 ) 56,993 Other (income) expense Interest income (12,226 ) (21,602 ) (1,278 ) (15 ) 35,101 (20 ) Interest expense 8,611 24,612 25,212 1,278 (35,101 ) 24,612 Gain on sale of asset — — (1,133 ) — — (1,133 ) Equity in (income) loss of subsidiaries (20,462 ) (12,977 ) (1,654 ) — 35,093 — Total other (income) expense (24,077 ) (9,967 ) 21,147 1,263 35,093 23,459 Income (loss) before income taxes 21,800 23,481 21,035 2,629 (35,411 ) 33,534 Provision for income taxes 507 3,782 6,977 975 — 12,241 Net income (loss) $ 21,293 $ 19,699 $ 14,058 $ 1,654 $ (35,411 ) $ 21,293 Comprehensive income, net of tax: Currency translation adjustments (8,779 ) (8,779 ) (8,779 ) (8,779 ) 26,337 (8,779 ) Total other comprehensive income (loss) (8,779 ) (8,779 ) (8,779 ) (8,779 ) 26,337 (8,779 ) Comprehensive income (loss) $ 12,514 $ 10,920 $ 5,279 $ (7,125 ) $ (9,074 ) $ 12,514 Condensed Consolidating Statements of Income and Comprehensive Income Nine Months Ended December 31, 2014 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 80,514 $ 402,967 $ 40,436 $ (2,936 ) $ 520,981 Other revenues — 308 3,506 1,104 (1,322 ) 3,596 Total revenues — 80,822 406,473 41,540 (4,258 ) 524,577 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 30,170 187,218 14,998 (3,962 ) 228,424 Gross profit — 50,652 219,255 26,542 (296 ) 296,153 Operating Expenses Advertising and promotion — 7,563 58,579 8,142 — 74,284 General and administrative 3,662 7,793 43,079 9,054 — 63,588 Depreciation and amortization 2,381 446 8,682 458 — 11,967 Total operating expenses 6,043 15,802 110,340 17,654 — 149,839 Operating income (loss) (6,043 ) 34,850 108,915 8,888 (296 ) 146,314 Other (income) expense Interest income (36,604 ) (52,546 ) (3,800 ) (55 ) 92,938 (67 ) Interest expense 25,788 57,505 63,350 3,800 (92,938 ) 57,505 Gain on sale of asset — — (1,133 ) — — (1,133 ) Equity in (income) loss of subsidiaries (53,718 ) (33,700 ) (2,565 ) — 89,983 — Total other (income) expense (64,534 ) (28,741 ) 55,852 3,745 89,983 56,305 Income (loss) before income taxes 58,491 63,591 53,063 5,143 (90,279 ) 90,009 Provision for income taxes 4,003 10,761 18,179 2,578 — 35,521 Net income (loss) $ 54,488 $ 52,830 $ 34,884 $ 2,565 $ (90,279 ) $ 54,488 Comprehensive income, net of tax: Currency translation adjustments (16,883 ) (16,883 ) (16,883 ) (16,883 ) 50,649 (16,883 ) Total other comprehensive income (loss) (16,883 ) (16,883 ) (16,883 ) (16,883 ) 50,649 (16,883 ) Comprehensive income (loss) $ 37,605 $ 35,947 $ 18,001 $ (14,318 ) $ (39,630 ) $ 37,605 Condensed Consolidating Balance Sheet December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 33,752 $ — $ — $ 15,221 $ — $ 48,973 Accounts receivable, net — 13,381 64,679 7,025 — 85,085 Inventories — 11,186 63,466 7,095 (1,076 ) 80,671 Deferred income tax assets 304 728 6,921 453 — 8,406 Prepaid expenses and other current assets 2,174 446 1,165 1,235 — 5,020 Total current assets 36,230 25,741 136,231 31,029 (1,076 ) 228,155 Property and equipment, net 9,383 227 2,085 607 — 12,302 Goodwill — 66,007 197,272 19,400 — 282,679 Intangible assets, net — 191,923 1,841,558 83,030 — 2,116,511 Other long-term assets — 1,352 — — — 1,352 Intercompany receivables 1,231,094 2,523,623 960,672 10,958 (4,726,347 ) — Investment in subsidiary 1,620,683 1,274,571 68,658 — (2,963,912 ) — Total Assets $ 2,897,390 $ 4,083,444 $ 3,206,476 $ 145,024 $ (7,691,335 ) $ 2,640,999 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 1,952 $ 5,668 $ 18,372 $ 2,547 $ — $ 28,539 Accrued interest payable — 9,359 — — — 9,359 Other accrued liabilities 10,276 2,132 31,852 4,563 — 48,823 Total current liabilities 12,228 17,159 50,224 7,110 — 86,721 Long-term debt Principal amount — 1,477,500 — — — 1,477,500 Less unamortized debt costs — (30,468 ) — — — (30,468 ) Long-term debt, net — 1,447,032 — — — 1,447,032 Deferred income tax liabilities — 59,256 324,211 18 — 383,485 Other long-term liabilities — — 2,664 159 — 2,823 Intercompany payables 2,164,224 1,010,637 1,478,338 73,148 (4,726,347 ) — Total Liabilities 2,176,452 2,534,084 1,855,437 80,435 (4,726,347 ) 1,920,061 Stockholders' Equity Common stock 530 — — — — 530 Additional paid-in capital 442,127 1,280,947 1,131,578 74,031 (2,486,556 ) 442,127 Treasury stock, at cost (5,121 ) — — — — (5,121 ) Accumulated other comprehensive income (loss), net of tax (29,974 ) (29,974 ) (29,974 ) (29,974 ) 89,922 (29,974 ) Retained earnings (accumulated deficit) 313,376 298,387 249,435 20,532 (568,354 ) 313,376 Total Stockholders' Equity 720,938 1,549,360 1,351,039 64,589 (2,964,988 ) 720,938 Total Liabilities and Stockholders' Equity $ 2,897,390 $ 4,083,444 $ 3,206,476 $ 145,024 $ (7,691,335 ) $ 2,640,999 Condensed Consolidating Balance Sheet March 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 11,387 $ — $ — $ 9,931 $ — $ 21,318 Accounts receivable, net — 14,539 66,523 6,796 — 87,858 Inventories — 8,667 60,297 6,182 (1,146 ) 74,000 Deferred income tax assets 452 674 6,497 474 — 8,097 Prepaid expenses and other current assets 5,731 141 3,804 758 — 10,434 Total current assets 17,570 24,021 137,121 24,141 (1,146 ) 201,707 Property and equipment, net 10,726 175 2,207 636 — 13,744 Goodwill — 66,007 204,205 20,439 — 290,651 Intangible assets, net — 192,325 1,854,798 87,577 — 2,134,700 Other long-term assets — 1,165 — — — 1,165 Intercompany receivables 1,210,017 2,607,054 668,169 8,764 (4,494,004 ) — Investment in subsidiary 1,545,575 1,228,535 65,564 — (2,839,674 ) — Total Assets $ 2,783,888 $ 4,119,282 $ 2,932,064 $ 141,557 $ (7,334,824 ) $ 2,641,967 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 1,959 $ 6,829 $ 32,898 $ 4,429 $ — $ 46,115 Accrued interest payable — 11,974 — — — 11,974 Other accrued liabilities 10,378 1,153 25,795 3,622 — 40,948 Total current liabilities 12,337 19,956 58,693 8,051 — 99,037 Long-term debt Principal amount — 1,593,600 — — — 1,593,600 Less unamortized debt costs — (32,327 ) — — — (32,327 ) Long-term debt, net — 1,561,273 — — — 1,561,273 Deferred income tax liabilities — 59,038 292,504 27 — 351,569 Other long-term liabilities — — 2,293 171 — 2,464 Intercompany payables 2,143,927 1,001,219 1,279,833 69,025 (4,494,004 ) — Total Liabilities 2,156,264 2,641,486 1,633,323 77,274 (4,494,004 ) 2,014,343 Stockholders' Equity Common stock 525 — — — — 525 Additional paid-in capital 426,584 1,280,948 1,131,578 74,031 (2,486,557 ) 426,584 Treasury stock, at cost (3,478 ) — — — — (3,478 ) Accumulated other comprehensive income (loss), net of tax (23,412 ) (23,412 ) (23,412 ) (23,412 ) 70,236 (23,412 ) Retained earnings (accumulated deficit) 227,405 220,260 190,575 13,664 (424,499 ) 227,405 Total Stockholders' Equity 627,624 1,477,796 1,298,741 64,283 (2,840,820 ) 627,624 Total Liabilities and Stockholders' Equity $ 2,783,888 $ 4,119,282 $ 2,932,064 $ 141,557 $ (7,334,824 ) $ 2,641,967 Condensed Consolidating Statement of Cash Flows Nine Months Ended December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 85,971 $ 78,127 $ 58,860 $ 6,868 $ (143,855 ) $ 85,971 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 3,032 444 13,686 316 — 17,478 Deferred income taxes 148 164 31,301 (22 ) — 31,591 Amortization of debt origination costs — 5,433 — — — 5,433 Stock-based compensation costs 7,057 — — 41 — 7,098 Loss on extinguishment of debt — 451 — — — 451 Gain on sale or disposal of property and equipment — — — (36 ) — (36 ) Equity in income of subsidiaries (84,458 ) (52,599 ) (6,868 ) — 143,925 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable — 1,158 2,188 (893 ) — 2,453 Inventories — (2,519 ) (3,014 ) (1,511 ) (70 ) (7,114 ) Prepaid expenses and other current assets 3,557 (305 ) 2,752 (532 ) — 5,472 Accounts payable (33 ) (1,161 ) (14,613 ) (1,746 ) — (17,553 ) Accrued liabilities (102 ) (1,636 ) 5,439 1,506 — 5,207 Net cash provided by operating activities 15,172 27,557 89,731 3,991 — 136,451 Investing Activities Purchases of property and equipment (1,741 ) (93 ) (212 ) (494 ) (2,540 ) Proceeds from the sale of property and equipment — — — 344 — 344 Proceeds from Insight Pharmaceuticals working capital arbitration settlement — — 7,237 — — 7,237 Net cash provided by (used in) investing activities (1,741 ) (93 ) 7,025 (150 ) — 5,041 Financing Activities Term loan repayments — (50,000 ) — — — (50,000 ) Borrowings under revolving credit agreement — 15,000 — — — 15,000 Repayments under revolving credit agreement — (81,100 ) — — — (81,100 ) Payments of debt origination costs — (4,211 ) — — — (4,211 ) Proceeds from exercise of stock options 6,600 — — — — 6,600 Proceeds from restricted stock exercises 544 — — — — 544 Excess tax benefits from share-based awards 1,850 — — — — 1,850 Fair value of shares surrendered as payment of tax withholding (2,187 ) — — — — (2,187 ) Intercompany activity, net 2,127 92,847 (96,756 ) 1,782 — — Net cash (used in) provided by financing activities 8,934 (27,464 ) (96,756 ) 1,782 — (113,504 ) Effect of exchange rate changes on cash and cash equivalents — — — (333 ) — (333 ) Increase in cash and cash equivalents 22,365 — — 5,290 — 27,655 Cash and cash equivalents - beginning of period 11,387 — — 9,931 — 21,318 Cash and cash equivalents - end of period $ 33,752 $ — $ — $ 15,221 $ — $ 48,973 Condensed Consolidating Statement of Cash Flows Nine Months Ended December 31, 2014 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non-Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 54,488 $ 52,830 $ 34,884 $ 2,565 $ (90,279 ) $ 54,488 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 2,381 446 8,682 458 — 11,967 Gain on sale of asset — — (1,133 ) — — (1,133 ) Deferred income taxes (69 ) 1,814 17,900 (128 ) — 19,517 Amortization of debt origination costs — 5,904 — — — 5,904 Stock-based compensation costs 4,919 — — — — 4,919 Lease termination costs — — 1,125 — — 1,125 Loss on sale or disposal of equipment — — — 321 — 321 Equity in income of subsidiaries (53,718 ) (33,700 ) (2,565 ) — 89,983 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable 466 (131 ) 6,556 (4,778 ) — 2,113 Inventories — 5,381 8,109 692 296 14,478 Prepaid expenses and other current assets 5,821 (140 ) 2,070 (153 ) — 7,598 Accounts payable (2,460 ) (2,652 ) (21,748 ) 1,408 — (25,452 ) Accrued liabilities 1,010 2,392 2,978 1,917 — 8,297 Net cash provided by operating activities 12,838 32,144 56,858 2,302 — 104,142 Investing Activities Purchases of property and equipment (3,167 ) — (419 ) (114 ) — (3,700 ) Proceeds from sale of business — — 18,500 — — 18,500 Proceeds from sale of asset — — 10,000 — — 10,000 Acquisition of Insight Pharmaceuticals, less cash acquired — — (749,666 ) — — (749,666 ) Acquisition of the Hydralyte brand — — — (77,991 ) — (77,991 ) Intercompany activity, net — (809,157 ) 731,166 77,991 — — Net cash (used in) provided by investing activities (3,167 ) (809,157 ) 9,581 (114 ) — (802,857 ) Financing Activities Term loan borrowings — 720,000 — — — 720,000 Term loan repayments — (80,000 ) — — — (80,000 ) Borrowings under revolving credit agreement — 124,600 — — — 124,600 Repayments under revolving credit agreement — (58,500 ) — — — (58,500 ) Payment of debt origination costs — (16,072 ) — — — (16,072 ) Proceeds from exercise of stock options 3,654 — — — — 3,654 Proceeds from restricted stock exercises 57 — — — — 57 Excess tax benefits from share-based awards 1,030 — — — — 1,030 Fair value of shares surrendered as payment of tax withholding (1,688 ) — — — — (1,688 ) Intercompany activity, net (23,093 ) 86,985 (65,950 ) 2,058 — — Net cash provided by (used in) financing activities (20,040 ) 777,013 (65,950 ) 2,058 — 693,081 Effect of exchange rate changes on cash and cash equivalents — — — (746 ) — (746 ) (Decrease) increase in cash and cash equivalents (10,369 ) — 489 3,500 — (6,380 ) Cash and cash equivalents - beginning of period 24,644 — — 3,687 — 28,331 Cash and cash equivalents - end of period $ 14,275 $ — $ 489 $ 7,187 $ — $ 21,951

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Acquisition of DenTek Oral Care, Inc. On November 23, 2015, we announced that we had entered into a definitive agreement to acquire DenTek Oral Care, Inc. ("DenTek"), a privately-held marketer and distributor of oral care products, for $225.0 million in cash. As of the date of this filing, we have not yet completed the acquisition, although we have recently received clearance under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and anticipate closing on this transaction in the near future. The transaction will be financed from a combination of available cash on hand, the use of our existing credit facilities, and funds made available pursuant to a short-term bridge loan, which we anticipate finalizing prior to the DenTek closing. We anticipate refinancing the bridge loan on a long-term basis in the near future. Director Resignation On February 1, 2016, Charles J. Hinkaty resigned as a Director of the Company. Mr. Hinkaty had served as a Director since May 2010. His resignation was not the result of a disagreement related to the Company's operations, policies or practices.

Business and Basis of Present26

Business and Basis of Presentation (Policies)	9 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in these Consolidated Financial Statements. In the opinion of management, these Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2016”) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the three and nine months ended December 31, 2015 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2016 . These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015 .
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships.
Accounts Receivable	Accounts Receivable We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.
Inventories	Inventories Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method. We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * * Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
Goodwill	Goodwill The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the product group level, which is one level below the operating segment level.
Intangible Assets	Intangible Assets Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
Debt Origination Costs	Debt Origination Costs We have incurred debt origination costs in connection with the issuance of long-term debt. Certain of these costs were recorded as deferred financing costs within long-term assets and others were recorded as a reduction to our long-term debt. These costs are amortized over the term of the related debt, using the effective interest method for our term loan facility and the straight-line method for our revolving credit facility. Effective April 1, 2015, in accordance with new accounting standards discussed below, we began reporting the costs related to our senior notes and the term loan facility as a reduction of debt. We continue to report the costs associated with our revolving credit facility as a long-term asset.
Revenue Recognition	Revenue Recognition Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience. As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of a promotional program, the estimated amounts are adjusted to actual results. Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.
Cost of Sales	Cost of Sales Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.
Advertising and Promotion Costs	Advertising and Promotion Costs Advertising and promotion costs are expensed as incurred. Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.
Stock-based Compensation	Stock-based Compensation We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.
Income Taxes	Income Taxes Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our tax uncertainties. We are subject to taxation in the United States and various state and foreign jurisdictions. We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.
Earnings Per Share	Earnings Per Share Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, and unvested restricted stock units, are included in the earnings per share calculation to the extent that they are dilutive.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In January 2016, the FASB issued Accounting Standards Update ("ASU") 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . For public business entities, the amendments in this update include the elimination of the requirement to disclose the method(s) and significant assumptions used to estimate fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet, the requirement to use the exit price notion when measuring fair value of financial instruments for disclosure purposes, the requirement to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments, the requirement for separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or accompanying notes to the financial statements, and the amendments clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity's other deferred tax assets. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption of the amendments in this update is not permitted, except that early application by public business entities to financial statements of fiscal years or interim periods that have not yet been issued or, by all other entities, that have not yet been made available for issuance are permitted as of the beginning of the fiscal year of adoption for the following amendment: An entity should present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk if the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. An entity should apply the amendments to this update by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes . The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. For public business entities, the amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In September 2015, the FASB issued ASU 2015-16, Simplifying the Accounting for Measurement-Period Adjustments . The amendments in this update require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. To simplify the accounting for adjustment made to provisional amounts recognized in a business combination, the amendments in this update eliminate the requirement to retrospectively account for those adjustments. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The adoption of ASU 2015-16 is not expected to have a material impact on our Consolidated Financial Statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory . The amendments in this update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards, under which an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs ("ASU 2015-03"). The amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. As permitted by the guidance, we have early adopted these provisions, as of the beginning of our first quarter of 2016. Given the absence of authoritative guidance within ASU 2015-03 for debt issuance costs related to line-of-credit arrangements, in August 2015, the FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements , stating that the SEC staff would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement . As a result, we reclassified $27.4 million of deferred financing costs as of March 31, 2015 from other long-term assets, and such costs are now presented as a direct deduction from the long-term debt liability. In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis . Update 2015-02 amended the process that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. The amendments in this update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-02 is not expected to have a material impact on our Consolidated Financial Statements. In January 2015, the FASB issued ASU 2015-01, Income Statement - Extraordinary and Unusual Items . The amendments in this update eliminate the concept of extraordinary items in Subtopic 225-20, which required entities to consider whether an underlying event or transaction is extraordinary. However, the amendments retain the presentation and disclosure guidance for items that are unusual in nature or occur infrequently. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The adoption of ASU 2015-01 is not expected to have a material impact on our Consolidated Financial Statements. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606 , which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In August 2015, the FASB issued ASU 2015-14, which deferred the effective date of ASU 2014-09 from annual and interim periods beginning after December 15, 2016 to annual and interim periods beginning after December 15, 2017. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity . Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 did not have a material impact on our Consolidated Financial Statements. Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

Business and Basis of Present27

Business and Basis of Presentation (Tables)	9 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Property and Equipment	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * * Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Property and equipment consist of the following: (In thousands) December 31, March 31, Components of Property and Equipment Machinery $ 4,085 $ 4,743 Computer equipment 13,843 11,339 Furniture and fixtures 2,406 2,484 Leasehold improvements 7,371 7,134 27,705 25,700 Accumulated depreciation (15,403 ) (11,956 ) Property and equipment, net $ 12,302 $ 13,744

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Dec. 31, 2015
Insight Pharmaceuticals
Business Acquisition [Line Items]
Allocation of Assets Acquired and Liabilities Assumed	The following table summarizes our allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date, after giving effect of the adjustments noted above. (In thousands) September 3, 2014 Cash acquired $ 3,507 Accounts receivable 26,012 Inventories 23,456 Deferred income tax assets - current 1,032 Prepaids and other current assets 1,341 Property, plant and equipment 2,308 Goodwill 96,323 Intangible assets 724,374 Total assets acquired 878,353 Accounts payable 16,079 Accrued expenses 8,539 Deferred income tax liabilities - long term 107,799 Total liabilities assumed 132,417 Total purchase price $ 745,936
Business Acquisition, Pro Forma Information	The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results. (In thousands, except per share data) Nine Months Ended December 31, 2014 Revenues $ 593,171 Net income $ 62,688 Earnings per share: Basic $ 1.20 Diluted $ 1.19
Hydralyte
Business Acquisition [Line Items]
Allocation of Assets Acquired and Liabilities Assumed	The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date. (In thousands) April 30, 2014 Inventories $ 1,970 Property, plant and equipment, net 1,267 Goodwill 1,224 Intangible assets, net 73,580 Total assets acquired 78,041 Accrued expenses 38 Other long-term liabilities 12 Total liabilities assumed 50 Net assets acquired $ 77,991

Accounts Receivable (Tables)

Accounts Receivable (Tables)	9 Months Ended
	Dec. 31, 2015
Receivables [Abstract]
Accounts Receivable	Accounts receivable consist of the following: (In thousands) December 31, March 31, Components of Accounts Receivable Trade accounts receivable $ 94,636 $ 95,411 Other receivables 1,436 2,353 96,072 97,764 Less allowances for discounts, returns and uncollectible accounts (10,987 ) (9,906 ) Accounts receivable, net $ 85,085 $ 87,858

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following: (In thousands) December 31, March 31, Components of Inventories Packaging and raw materials $ 8,097 $ 7,588 Finished goods 72,574 66,412 Inventories $ 80,671 $ 74,000

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * * Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Property and equipment consist of the following: (In thousands) December 31, March 31, Components of Property and Equipment Machinery $ 4,085 $ 4,743 Computer equipment 13,843 11,339 Furniture and fixtures 2,406 2,484 Leasehold improvements 7,371 7,134 27,705 25,700 Accumulated depreciation (15,403 ) (11,956 ) Property and equipment, net $ 12,302 $ 13,744

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Goodwill	A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC Healthcare International OTC Healthcare Household Cleaning Consolidated Balance — March 31, 2015 $ 263,411 $ 20,440 $ 6,800 $ 290,651 Adjustments (6,932 ) — — (6,932 ) Effects of foreign currency exchange rates — (1,040 ) — (1,040 ) Balance — December 31, 2015 $ 256,479 $ 19,400 $ 6,800 $ 282,679

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Intangible Assets	A reconciliation of the activity affecting intangible assets is as follows: (In thousands) Indefinite Lived Trademarks Finite Lived Trademarks Totals Gross Carrying Amounts Balance — March 31, 2015 $ 1,873,404 $ 358,066 $ 2,231,470 Effects of foreign currency exchange rates (4,383 ) (70 ) (4,453 ) Balance — December 31, 2015 1,869,021 357,996 2,227,017 Accumulated Amortization Balance — March 31, 2015 — 96,770 96,770 Additions — 13,745 13,745 Effects of foreign currency exchange rates — (9 ) (9 ) Balance — December 31, 2015 — 110,506 110,506 Intangible assets, net - December 31, 2015 $ 1,869,021 $ 247,490 $ 2,116,511 Intangible Assets, net by Reportable Segment: North American OTC Healthcare $ 1,676,991 $ 223,272 $ 1,900,263 International OTC Healthcare 81,758 1,104 82,862 Household Cleaning 110,272 23,114 133,386 Intangible assets, net - December 31, 2015 $ 1,869,021 $ 247,490 $ 2,116,511
Schedule of Expected Amortization Expense	At December 31, 2015 , finite-lived intangible assets are being amortized over a period of 10 to 30 years, and the associated amortization expense is expected to be as follows: (In thousands) Year Ending March 31, Amount 2016 (Remaining three months ending March 31, 2016) $ 4,466 2017 17,863 2018 17,863 2019 17,863 2020 17,863 Thereafter 171,572 $ 247,490

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	9 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities consist of the following: (In thousands) December 31, March 31, Accrued marketing costs $ 24,757 $ 16,903 Accrued compensation costs 6,837 8,840 Accrued broker commissions 1,231 1,134 Income taxes payable 3,456 2,642 Accrued professional fees 2,229 2,769 Deferred rent 825 1,021 Accrued production costs 5,303 5,610 Accrued lease termination costs 544 669 Other accrued liabilities 3,641 1,360 $ 48,823 $ 40,948

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) December 31, March 31, 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021. $ 400,000 $ 400,000 2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020. 250,000 250,000 2012 Term B-3 Loans bearing interest at the Borrower's option at either a base rate with a floor of 1.75% plus applicable margin or LIBOR with a floor of 0.75% plus applicable margin, due on September 3, 2021. 827,500 877,500 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on June 9, 2020. — 66,100 Total long-term debt (including current portion) 1,477,500 1,593,600 Current portion of long-term debt — — Long-term debt 1,477,500 1,593,600 Less: unamortized debt costs (30,468 ) (32,327 ) Long-term debt, net $ 1,447,032 $ 1,561,273
Aggregate Future Principal Payments	As of December 31, 2015, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows: (In thousands) Year Ending March 31, Amount 2016 (remaining three months ending March 31, 2016) $ — 2017 — 2018 — 2019 6,969 2020 258,525 Thereafter 1,212,006 $ 1,477,500

Accumulated Other Comprehensi36

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income	The table below presents accumulated other comprehensive loss (“AOCI”), which affects equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners. AOCI consisted of the following at December 31, 2015 and March 31, 2015 : December 31, March 31, (In thousands) 2015 2015 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (29,974 ) $ (23,412 ) Accumulated other comprehensive loss, net of tax $ (29,974 ) $ (23,412 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2015 2014 2015 2014 Numerator Net income $ 27,995 $ 21,293 $ 85,971 $ 54,488 Denominator Denominator for basic earnings per share — weighted average shares outstanding 52,824 52,278 52,727 52,110 Dilutive effect of unvested restricted stock units and options issued to employees and directors 379 452 379 512 Denominator for diluted earnings per share 53,203 52,730 53,106 52,622 Earnings per Common Share: Basic net earnings per share $ 0.53 $ 0.41 $ 1.63 $ 1.05 Diluted net earnings per share $ 0.53 $ 0.40 $ 1.62 $ 1.04

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Restricted Shares	A summary of the Company's restricted shares granted under the Plan is presented below: Restricted Shares Shares (in thousands) Weighted- Average Grant-Date Fair Value Nine months ended December 31, 2014 Vested and nonvested at March 31, 2014 437.5 $ 16.76 Granted 104.4 33.30 Vested and issued (122.8 ) 13.62 Forfeited (21.3 ) 20.77 Vested and nonvested at December 31, 2014 397.8 21.86 Vested at December 31, 2014 76.6 11.62 Nine months ended December 31, 2015 Vested and nonvested at March 31, 2015 362.3 $ 22.74 Granted 266.1 42.41 Vested and issued (153.6 ) 18.16 Forfeited (1.4 ) 33.50 Vested and nonvested at December 31, 2015 473.4 35.25 Vested at December 31, 2015 69.8 14.76
Fair Value of Options Granted	Nine Months Ended December 31, 2015 2014 Expected volatility 40.2 % 47.3 % Expected dividends $ — $ — Expected term in years 6.0 6.0 Risk-free rate 1.7 % 2.2 %
Stock Option Activity	A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Nine months ended December 31, 2014: Outstanding at March 31, 2014 994.9 $ 15.24 Granted 307.5 33.50 Exercised (363.4 ) 10.05 Forfeited or expired (47.5 ) 25.76 Outstanding at December 31, 2014 891.5 23.09 7.9 $ 10,368 Exercisable at December 31, 2014 335.1 15.01 6.7 6,604 Nine months ended December 31, 2015: Outstanding at March 31, 2015 871.2 $ 23.40 Granted 208.2 42.13 Exercised (336.9 ) 18.99 Forfeited or expired (2.1 ) 38.21 Outstanding at December 31, 2015 740.4 30.63 7.9 $ 15,325 Exercisable at December 31, 2015 313.5 21.68 6.7 9,341

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	The following summarizes future minimum lease payments for our operating leases as of December 31, 2015 (a) : (In thousands) Year Ending March 31, Facilities Equipment Total 2016 (Remaining three months ending March 31, 2016) $ 455 $ 47 $ 502 2017 1,923 77 2,000 2018 1,934 — 1,934 2019 1,926 — 1,926 2020 1,757 — 1,757 Thereafter 817 — 817 $ 8,812 $ 124 $ 8,936 (a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.2 million due in the future under noncancelable subleases. The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals: (In thousands) December 31, 2015 March 31, 2015 Minimum lease payments $ 8,936 $ 9,957 Less: Sublease rentals (1,224 ) (1,401 ) $ 7,712 $ 8,556
Unrecorded Unconditional Purchase Obligations Disclosure	Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement. (In thousands) Year Ending March 31, Amount 2016 (Remaining three months ending March 31, 2016) 266 2017 1,044 2018 1,013 2019 982 2020 560 Thereafter — $ 3,865

Business Segments (Tables)

Business Segments (Tables)	9 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Information about our Operating and Reportable Segments	The tables below summarize information about our reportable segments. Three Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues* $ 165,278 $ 13,812 $ 20,623 $ 199,713 Elimination of intersegment revenues (228 ) — — (228 ) Third-party segment revenues 165,050 13,812 20,623 199,485 Other revenues* — 9 701 710 Total segment revenues 165,050 13,821 21,324 200,195 Cost of sales 62,654 4,965 15,792 83,411 Gross profit 102,396 8,856 5,532 116,784 Advertising and promotion 26,472 2,838 625 29,935 Contribution margin $ 75,924 $ 6,018 $ 4,907 86,849 Other operating expenses 24,206 Operating income 62,643 Other expense 19,462 Income before income taxes 43,181 Provision for income taxes 15,186 Net income $ 27,995 Nine Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues* $ 489,224 $ 43,254 $ 65,984 $ 598,462 Elimination of intersegment revenues (2,428 ) — — (2,428 ) Third-party segment revenues 486,796 43,254 65,984 596,034 Other revenues* 14 41 2,303 2,358 Total segment revenues 486,810 43,295 68,287 598,392 Cost of sales 182,279 16,347 50,806 249,432 Gross profit 304,531 26,948 17,481 348,960 Advertising and promotion 74,107 8,338 1,805 84,250 Contribution margin $ 230,424 $ 18,610 $ 15,676 264,710 Other operating expenses 69,664 Operating income 195,046 Other expense 62,464 Income before income taxes 132,582 Provision for income taxes 46,611 Net income $ 85,971 Three Months Ended December 31, 2014 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues* $ 162,163 $ 15,563 $ 20,218 $ 197,944 Elimination of intersegment revenues (1,509 ) — — (1,509 ) Third-party segment revenues 160,654 15,563 20,218 196,435 Other revenues 151 4 1,016 1,171 Total segment revenues 160,805 15,567 21,234 197,606 Cost of sales 63,479 6,247 16,135 85,861 Gross profit 97,326 9,320 5,099 111,745 Advertising and promotion 26,779 2,776 589 30,144 Contribution margin $ 70,547 $ 6,544 $ 4,510 81,601 Other operating expenses 24,608 Operating income 56,993 Other expense 23,459 Income before income taxes 33,534 Provision for income taxes 12,241 Net income $ 21,293 Nine Months Ended December 31, 2014 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues* $ 412,703 $ 45,157 $ 66,057 $ 523,917 Elimination of intersegment revenues (2,936 ) — — (2,936 ) Third-party segment revenues 409,767 45,157 66,057 520,981 Other revenues 478 62 3,056 3,596 Total segment revenues 410,245 45,219 69,113 524,577 Cost of sales 158,005 17,926 52,493 228,424 Gross profit 252,240 27,293 16,620 296,153 Advertising and promotion 64,573 8,151 1,560 74,284 Contribution margin $ 187,667 $ 19,142 $ 15,060 221,869 Other operating expenses 75,555 Operating income 146,314 Other expense 56,305 Income before income taxes 90,009 Provision for income taxes 35,521 Net income $ 54,488 * Certain immaterial amounts relating to intersegment revenues and other revenues were reclassified between the International OTC Healthcare segment and the North American OTC Healthcare segment. There were no changes to the consolidated financial statements for any periods presented.
Information about our Revenues from Similar Product Groups	The tables below summarize information about our segment revenues from similar product groups. Three Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 30,454 $ 450 $ — $ 30,904 Cough & Cold 30,466 3,696 — 34,162 Women's Health 33,521 877 — 34,398 Gastrointestinal 17,401 5,517 — 22,918 Eye & Ear Care 21,927 2,622 — 24,549 Dermatologicals 19,734 524 — 20,258 Oral Care 9,996 126 — 10,122 Other OTC 1,551 9 — 1,560 Household Cleaning — — 21,324 21,324 Total segment revenues $ 165,050 $ 13,821 $ 21,324 $ 200,195 Nine Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 86,996 $ 1,668 $ — $ 88,664 Cough & Cold 74,661 12,968 — 87,629 Women's Health 100,036 2,381 — 102,417 Gastrointestinal 56,782 14,667 — 71,449 Eye & Ear Care 71,137 9,415 — 80,552 Dermatologicals 63,026 1,669 — 64,695 Oral Care 29,706 509 — 30,215 Other OTC 4,466 18 — 4,484 Household Cleaning — — 68,287 68,287 Total segment revenues $ 486,810 $ 43,295 $ 68,287 $ 598,392 Three Months Ended December 31, 2014 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 28,187 $ 657 $ — $ 28,844 Cough & Cold 31,927 3,831 — 35,758 Women's Health 31,364 589 — 31,953 Gastrointestinal 17,365 6,668 — 24,033 Eye & Ear Care 20,528 3,069 — 23,597 Dermatologicals 17,663 570 — 18,233 Oral Care 12,300 172 — 12,472 Other OTC 1,471 11 — 1,482 Household Cleaning — — 21,234 21,234 Total segment revenues $ 160,805 $ 15,567 $ 21,234 $ 197,606 Nine Months Ended December 31, 2014 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 82,290 $ 2,114 $ — $ 84,404 Cough & Cold 76,741 14,090 — 90,831 Women's Health 40,851 1,765 — 42,616 Gastrointestinal 58,899 14,764 — 73,663 Eye & Ear Care 64,086 10,311 — 74,397 Dermatologicals 47,383 1,799 — 49,182 Oral Care 35,421 361 — 35,782 Other OTC 4,574 15 — 4,589 Household Cleaning — — 69,113 69,113 Total segment revenues $ 410,245 $ 45,219 $ 69,113 $ 524,577
Allocation of Long-Term Assets to Segments	At December 31, 2015 , approximately 95.7% of our consolidated goodwill and intangible assets were located in the United States and approximately 4.3% were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: (In thousands) North American OTC International OTC Household Cleaning Consolidated Goodwill $ 256,479 $ 19,400 $ 6,800 $ 282,679 Intangible assets Indefinite-lived 1,676,991 81,758 110,272 1,869,021 Finite-lived 223,272 1,104 23,114 247,490 Intangible assets, net 1,900,263 82,862 133,386 2,116,511 Total $ 2,156,742 $ 102,262 $ 140,186 $ 2,399,190

Condensed Consolidating Finan41

Condensed Consolidating Financial Statements (Tables)	9 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Statements of Income and Comprehensive Income	Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 27,598 $ 159,783 $ 12,332 $ (228 ) $ 199,485 Other revenues — 98 700 356 (444 ) 710 Total revenues — 27,696 160,483 12,688 (672 ) 200,195 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 11,796 68,148 4,448 (981 ) 83,411 Gross profit — 15,900 92,335 8,240 309 116,784 Operating Expenses Advertising and promotion — 1,881 25,251 2,803 — 29,935 General and administrative 1,370 1,789 13,463 1,513 — 18,135 Depreciation and amortization 1,013 151 4,794 113 — 6,071 Total operating expenses 2,383 3,821 43,508 4,429 — 54,141 Operating income (loss) (2,383 ) 12,079 48,827 3,811 309 62,643 Other (income) expense Interest income (12,141 ) (21,569 ) (1,124 ) (128 ) 34,931 (31 ) Interest expense 8,602 19,443 25,255 1,124 (34,931 ) 19,493 Equity in (income) loss of subsidiaries (27,711 ) (15,898 ) (2,033 ) — 45,642 — Total other (income) expense (31,250 ) (18,024 ) 22,098 996 45,642 19,462 Income (loss) before income taxes 28,867 30,103 26,729 2,815 (45,333 ) 43,181 Provision for income taxes 872 4,950 8,582 782 — 15,186 Net income (loss) $ 27,995 $ 25,153 $ 18,147 $ 2,033 $ (45,333 ) $ 27,995 Comprehensive income, net of tax: Currency translation adjustments 4,922 4,922 4,922 4,922 (14,766 ) 4,922 Total other comprehensive income (loss) 4,922 4,922 4,922 4,922 (14,766 ) 4,922 Comprehensive income (loss) $ 32,917 $ 30,075 $ 23,069 $ 6,955 $ (60,099 ) $ 32,917 Condensed Consolidating Statements of Income and Comprehensive Income Nine Months Ended December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 83,438 $ 477,079 $ 37,945 $ (2,428 ) $ 596,034 Other revenues — 273 2,317 1,397 (1,629 ) 2,358 Total revenues — 83,711 479,396 39,342 (4,057 ) 598,392 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 33,105 206,646 13,808 (4,127 ) 249,432 Gross profit — 50,606 272,750 25,534 70 348,960 Operating Expenses Advertising and promotion — 7,602 68,412 8,236 — 84,250 General and administrative 3,884 5,644 38,326 4,332 — 52,186 Depreciation and amortization 3,032 444 13,686 316 — 17,478 Total operating expenses 6,916 13,690 120,424 12,884 — 153,914 Operating income (loss) (6,916 ) 36,916 152,326 12,650 70 195,046 Other (income) expense Interest income (36,351 ) (64,584 ) (3,513 ) (366 ) 104,723 (91 ) Interest expense 26,056 61,654 75,604 3,513 (104,723 ) 62,104 Loss on extinguishment of debt — 451 — — — 451 Equity in (income) loss of subsidiaries (84,458 ) (52,599 ) (6,868 ) — 143,925 — Total other (income) expense (94,753 ) (55,078 ) 65,223 3,147 143,925 62,464 Income (loss) before income taxes 87,837 91,994 87,103 9,503 (143,855 ) 132,582 Provision for income taxes 1,866 13,867 28,243 2,635 — 46,611 Net income (loss) $ 85,971 $ 78,127 $ 58,860 $ 6,868 $ (143,855 ) $ 85,971 Comprehensive income, net of tax: Currency translation adjustments (6,562 ) (6,562 ) (6,562 ) (6,562 ) 19,686 (6,562 ) Total other comprehensive income (loss) (6,562 ) (6,562 ) (6,562 ) (6,562 ) 19,686 (6,562 ) Comprehensive income (loss) $ 79,409 $ 71,565 $ 52,298 $ 306 $ (124,169 ) $ 79,409 Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended December 31, 2014 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 27,937 $ 155,733 $ 14,273 $ (1,508 ) $ 196,435 Other revenues — 83 1,166 266 (344 ) 1,171 Total revenues — 28,020 156,899 14,539 (1,852 ) 197,606 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 10,296 71,891 5,208 (1,534 ) 85,861 Gross profit — 17,724 85,008 9,331 (318 ) 111,745 Operating Expenses Advertising and promotion — 2,175 25,202 2,767 — 30,144 General and administrative 1,408 1,879 13,760 2,407 — 19,454 Depreciation and amortization 869 156 3,864 265 — 5,154 Total operating expenses 2,277 4,210 42,826 5,439 — 54,752 Operating income (loss) (2,277 ) 13,514 42,182 3,892 (318 ) 56,993 Other (income) expense Interest income (12,226 ) (21,602 ) (1,278 ) (15 ) 35,101 (20 ) Interest expense 8,611 24,612 25,212 1,278 (35,101 ) 24,612 Gain on sale of asset — — (1,133 ) — — (1,133 ) Equity in (income) loss of subsidiaries (20,462 ) (12,977 ) (1,654 ) — 35,093 — Total other (income) expense (24,077 ) (9,967 ) 21,147 1,263 35,093 23,459 Income (loss) before income taxes 21,800 23,481 21,035 2,629 (35,411 ) 33,534 Provision for income taxes 507 3,782 6,977 975 — 12,241 Net income (loss) $ 21,293 $ 19,699 $ 14,058 $ 1,654 $ (35,411 ) $ 21,293 Comprehensive income, net of tax: Currency translation adjustments (8,779 ) (8,779 ) (8,779 ) (8,779 ) 26,337 (8,779 ) Total other comprehensive income (loss) (8,779 ) (8,779 ) (8,779 ) (8,779 ) 26,337 (8,779 ) Comprehensive income (loss) $ 12,514 $ 10,920 $ 5,279 $ (7,125 ) $ (9,074 ) $ 12,514 Condensed Consolidating Statements of Income and Comprehensive Income Nine Months Ended December 31, 2014 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 80,514 $ 402,967 $ 40,436 $ (2,936 ) $ 520,981 Other revenues — 308 3,506 1,104 (1,322 ) 3,596 Total revenues — 80,822 406,473 41,540 (4,258 ) 524,577 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 30,170 187,218 14,998 (3,962 ) 228,424 Gross profit — 50,652 219,255 26,542 (296 ) 296,153 Operating Expenses Advertising and promotion — 7,563 58,579 8,142 — 74,284 General and administrative 3,662 7,793 43,079 9,054 — 63,588 Depreciation and amortization 2,381 446 8,682 458 — 11,967 Total operating expenses 6,043 15,802 110,340 17,654 — 149,839 Operating income (loss) (6,043 ) 34,850 108,915 8,888 (296 ) 146,314 Other (income) expense Interest income (36,604 ) (52,546 ) (3,800 ) (55 ) 92,938 (67 ) Interest expense 25,788 57,505 63,350 3,800 (92,938 ) 57,505 Gain on sale of asset — — (1,133 ) — — (1,133 ) Equity in (income) loss of subsidiaries (53,718 ) (33,700 ) (2,565 ) — 89,983 — Total other (income) expense (64,534 ) (28,741 ) 55,852 3,745 89,983 56,305 Income (loss) before income taxes 58,491 63,591 53,063 5,143 (90,279 ) 90,009 Provision for income taxes 4,003 10,761 18,179 2,578 — 35,521 Net income (loss) $ 54,488 $ 52,830 $ 34,884 $ 2,565 $ (90,279 ) $ 54,488 Comprehensive income, net of tax: Currency translation adjustments (16,883 ) (16,883 ) (16,883 ) (16,883 ) 50,649 (16,883 ) Total other comprehensive income (loss) (16,883 ) (16,883 ) (16,883 ) (16,883 ) 50,649 (16,883 ) Comprehensive income (loss) $ 37,605 $ 35,947 $ 18,001 $ (14,318 ) $ (39,630 ) $ 37,605
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 33,752 $ — $ — $ 15,221 $ — $ 48,973 Accounts receivable, net — 13,381 64,679 7,025 — 85,085 Inventories — 11,186 63,466 7,095 (1,076 ) 80,671 Deferred income tax assets 304 728 6,921 453 — 8,406 Prepaid expenses and other current assets 2,174 446 1,165 1,235 — 5,020 Total current assets 36,230 25,741 136,231 31,029 (1,076 ) 228,155 Property and equipment, net 9,383 227 2,085 607 — 12,302 Goodwill — 66,007 197,272 19,400 — 282,679 Intangible assets, net — 191,923 1,841,558 83,030 — 2,116,511 Other long-term assets — 1,352 — — — 1,352 Intercompany receivables 1,231,094 2,523,623 960,672 10,958 (4,726,347 ) — Investment in subsidiary 1,620,683 1,274,571 68,658 — (2,963,912 ) — Total Assets $ 2,897,390 $ 4,083,444 $ 3,206,476 $ 145,024 $ (7,691,335 ) $ 2,640,999 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 1,952 $ 5,668 $ 18,372 $ 2,547 $ — $ 28,539 Accrued interest payable — 9,359 — — — 9,359 Other accrued liabilities 10,276 2,132 31,852 4,563 — 48,823 Total current liabilities 12,228 17,159 50,224 7,110 — 86,721 Long-term debt Principal amount — 1,477,500 — — — 1,477,500 Less unamortized debt costs — (30,468 ) — — — (30,468 ) Long-term debt, net — 1,447,032 — — — 1,447,032 Deferred income tax liabilities — 59,256 324,211 18 — 383,485 Other long-term liabilities — — 2,664 159 — 2,823 Intercompany payables 2,164,224 1,010,637 1,478,338 73,148 (4,726,347 ) — Total Liabilities 2,176,452 2,534,084 1,855,437 80,435 (4,726,347 ) 1,920,061 Stockholders' Equity Common stock 530 — — — — 530 Additional paid-in capital 442,127 1,280,947 1,131,578 74,031 (2,486,556 ) 442,127 Treasury stock, at cost (5,121 ) — — — — (5,121 ) Accumulated other comprehensive income (loss), net of tax (29,974 ) (29,974 ) (29,974 ) (29,974 ) 89,922 (29,974 ) Retained earnings (accumulated deficit) 313,376 298,387 249,435 20,532 (568,354 ) 313,376 Total Stockholders' Equity 720,938 1,549,360 1,351,039 64,589 (2,964,988 ) 720,938 Total Liabilities and Stockholders' Equity $ 2,897,390 $ 4,083,444 $ 3,206,476 $ 145,024 $ (7,691,335 ) $ 2,640,999 Condensed Consolidating Balance Sheet March 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 11,387 $ — $ — $ 9,931 $ — $ 21,318 Accounts receivable, net — 14,539 66,523 6,796 — 87,858 Inventories — 8,667 60,297 6,182 (1,146 ) 74,000 Deferred income tax assets 452 674 6,497 474 — 8,097 Prepaid expenses and other current assets 5,731 141 3,804 758 — 10,434 Total current assets 17,570 24,021 137,121 24,141 (1,146 ) 201,707 Property and equipment, net 10,726 175 2,207 636 — 13,744 Goodwill — 66,007 204,205 20,439 — 290,651 Intangible assets, net — 192,325 1,854,798 87,577 — 2,134,700 Other long-term assets — 1,165 — — — 1,165 Intercompany receivables 1,210,017 2,607,054 668,169 8,764 (4,494,004 ) — Investment in subsidiary 1,545,575 1,228,535 65,564 — (2,839,674 ) — Total Assets $ 2,783,888 $ 4,119,282 $ 2,932,064 $ 141,557 $ (7,334,824 ) $ 2,641,967 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 1,959 $ 6,829 $ 32,898 $ 4,429 $ — $ 46,115 Accrued interest payable — 11,974 — — — 11,974 Other accrued liabilities 10,378 1,153 25,795 3,622 — 40,948 Total current liabilities 12,337 19,956 58,693 8,051 — 99,037 Long-term debt Principal amount — 1,593,600 — — — 1,593,600 Less unamortized debt costs — (32,327 ) — — — (32,327 ) Long-term debt, net — 1,561,273 — — — 1,561,273 Deferred income tax liabilities — 59,038 292,504 27 — 351,569 Other long-term liabilities — — 2,293 171 — 2,464 Intercompany payables 2,143,927 1,001,219 1,279,833 69,025 (4,494,004 ) — Total Liabilities 2,156,264 2,641,486 1,633,323 77,274 (4,494,004 ) 2,014,343 Stockholders' Equity Common stock 525 — — — — 525 Additional paid-in capital 426,584 1,280,948 1,131,578 74,031 (2,486,557 ) 426,584 Treasury stock, at cost (3,478 ) — — — — (3,478 ) Accumulated other comprehensive income (loss), net of tax (23,412 ) (23,412 ) (23,412 ) (23,412 ) 70,236 (23,412 ) Retained earnings (accumulated deficit) 227,405 220,260 190,575 13,664 (424,499 ) 227,405 Total Stockholders' Equity 627,624 1,477,796 1,298,741 64,283 (2,840,820 ) 627,624 Total Liabilities and Stockholders' Equity $ 2,783,888 $ 4,119,282 $ 2,932,064 $ 141,557 $ (7,334,824 ) $ 2,641,967
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows Nine Months Ended December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 85,971 $ 78,127 $ 58,860 $ 6,868 $ (143,855 ) $ 85,971 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 3,032 444 13,686 316 — 17,478 Deferred income taxes 148 164 31,301 (22 ) — 31,591 Amortization of debt origination costs — 5,433 — — — 5,433 Stock-based compensation costs 7,057 — — 41 — 7,098 Loss on extinguishment of debt — 451 — — — 451 Gain on sale or disposal of property and equipment — — — (36 ) — (36 ) Equity in income of subsidiaries (84,458 ) (52,599 ) (6,868 ) — 143,925 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable — 1,158 2,188 (893 ) — 2,453 Inventories — (2,519 ) (3,014 ) (1,511 ) (70 ) (7,114 ) Prepaid expenses and other current assets 3,557 (305 ) 2,752 (532 ) — 5,472 Accounts payable (33 ) (1,161 ) (14,613 ) (1,746 ) — (17,553 ) Accrued liabilities (102 ) (1,636 ) 5,439 1,506 — 5,207 Net cash provided by operating activities 15,172 27,557 89,731 3,991 — 136,451 Investing Activities Purchases of property and equipment (1,741 ) (93 ) (212 ) (494 ) (2,540 ) Proceeds from the sale of property and equipment — — — 344 — 344 Proceeds from Insight Pharmaceuticals working capital arbitration settlement — — 7,237 — — 7,237 Net cash provided by (used in) investing activities (1,741 ) (93 ) 7,025 (150 ) — 5,041 Financing Activities Term loan repayments — (50,000 ) — — — (50,000 ) Borrowings under revolving credit agreement — 15,000 — — — 15,000 Repayments under revolving credit agreement — (81,100 ) — — — (81,100 ) Payments of debt origination costs — (4,211 ) — — — (4,211 ) Proceeds from exercise of stock options 6,600 — — — — 6,600 Proceeds from restricted stock exercises 544 — — — — 544 Excess tax benefits from share-based awards 1,850 — — — — 1,850 Fair value of shares surrendered as payment of tax withholding (2,187 ) — — — — (2,187 ) Intercompany activity, net 2,127 92,847 (96,756 ) 1,782 — — Net cash (used in) provided by financing activities 8,934 (27,464 ) (96,756 ) 1,782 — (113,504 ) Effect of exchange rate changes on cash and cash equivalents — — — (333 ) — (333 ) Increase in cash and cash equivalents 22,365 — — 5,290 — 27,655 Cash and cash equivalents - beginning of period 11,387 — — 9,931 — 21,318 Cash and cash equivalents - end of period $ 33,752 $ — $ — $ 15,221 $ — $ 48,973 Condensed Consolidating Statement of Cash Flows Nine Months Ended December 31, 2014 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non-Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 54,488 $ 52,830 $ 34,884 $ 2,565 $ (90,279 ) $ 54,488 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 2,381 446 8,682 458 — 11,967 Gain on sale of asset — — (1,133 ) — — (1,133 ) Deferred income taxes (69 ) 1,814 17,900 (128 ) — 19,517 Amortization of debt origination costs — 5,904 — — — 5,904 Stock-based compensation costs 4,919 — — — — 4,919 Lease termination costs — — 1,125 — — 1,125 Loss on sale or disposal of equipment — — — 321 — 321 Equity in income of subsidiaries (53,718 ) (33,700 ) (2,565 ) — 89,983 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable 466 (131 ) 6,556 (4,778 ) — 2,113 Inventories — 5,381 8,109 692 296 14,478 Prepaid expenses and other current assets 5,821 (140 ) 2,070 (153 ) — 7,598 Accounts payable (2,460 ) (2,652 ) (21,748 ) 1,408 — (25,452 ) Accrued liabilities 1,010 2,392 2,978 1,917 — 8,297 Net cash provided by operating activities 12,838 32,144 56,858 2,302 — 104,142 Investing Activities Purchases of property and equipment (3,167 ) — (419 ) (114 ) — (3,700 ) Proceeds from sale of business — — 18,500 — — 18,500 Proceeds from sale of asset — — 10,000 — — 10,000 Acquisition of Insight Pharmaceuticals, less cash acquired — — (749,666 ) — — (749,666 ) Acquisition of the Hydralyte brand — — — (77,991 ) — (77,991 ) Intercompany activity, net — (809,157 ) 731,166 77,991 — — Net cash (used in) provided by investing activities (3,167 ) (809,157 ) 9,581 (114 ) — (802,857 ) Financing Activities Term loan borrowings — 720,000 — — — 720,000 Term loan repayments — (80,000 ) — — — (80,000 ) Borrowings under revolving credit agreement — 124,600 — — — 124,600 Repayments under revolving credit agreement — (58,500 ) — — — (58,500 ) Payment of debt origination costs — (16,072 ) — — — (16,072 ) Proceeds from exercise of stock options 3,654 — — — — 3,654 Proceeds from restricted stock exercises 57 — — — — 57 Excess tax benefits from share-based awards 1,030 — — — — 1,030 Fair value of shares surrendered as payment of tax withholding (1,688 ) — — — — (1,688 ) Intercompany activity, net (23,093 ) 86,985 (65,950 ) 2,058 — — Net cash provided by (used in) financing activities (20,040 ) 777,013 (65,950 ) 2,058 — 693,081 Effect of exchange rate changes on cash and cash equivalents — — — (746 ) — (746 ) (Decrease) increase in cash and cash equivalents (10,369 ) — 489 3,500 — (6,380 ) Cash and cash equivalents - beginning of period 24,644 — — 3,687 — 28,331 Cash and cash equivalents - end of period $ 14,275 $ — $ 489 $ 7,187 $ — $ 21,951

Business and Basis of Present42

Business and Basis of Presentation (Other Balance Sheet and Income Statement Items) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage, subsidiaries	100.00%		100.00%
Term of original maturities, cash equivalents, up to and including			3 months
Shipping, warehousing and handling costs	$ 10.1	$ 9.2	$ 29.2	$ 26.3

Business and Basis of Present43

Business and Basis of Presentation (Property and Equipment) (Details)	9 Months Ended
	Dec. 31, 2015
Machinery
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	5 years
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years

Business and Basis of Present44

Business and Basis of Presentation (Intangible Assets) (Details)	9 Months Ended
	Dec. 31, 2015
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	30 years

Business and Basis of Present45

Business and Basis of Presentation (Debt Issuance Costs) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Debt Instrument [Line Items]
Decrease in other long-term assets	$ (1,352)	$ (1,165)
Adjustments for new accounting pronouncement
Debt Instrument [Line Items]
Decrease in other long-term assets		$ 27,400

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) $ in Thousands	Sep. 03, 2014USD ($)brand	Jun. 30, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Mar. 31, 2015USD ($)	Apr. 30, 2014USD ($)
Business Acquisition [Line Items]
Proceeds from Insight Pharmaceuticals working capital arbitration settlement			$ 7,237	$ 0
Purchased amortizable intangible assets, weighted average remaining period			13 years 10 months 9 days
Goodwill			$ 282,679		$ 290,651
Insight Pharmaceuticals
Business Acquisition [Line Items]
Purchase price of acquisition	$ 745,900
Proceeds from Insight Pharmaceuticals working capital arbitration settlement	$ 7,200
Number of pharmaceutical brands acquired as a result of acquisition | brand	27
Number of brands sold | brand	1
Non-amortizable intangible assets	$ 599,600
Amortizable intangible assets	124,800
Purchased amortizable intangible assets, weighted average useful life			16 years 2 months 12 days
Purchased amortizable intangible assets, weighted average remaining period			14 years 10 months
Goodwill	96,323
Value of assets sold on acquisition date, excluded from purchase price	18,500
Non-amortizable intangible assets	724,374
Insight Pharmaceuticals | Intangible assets
Business Acquisition [Line Items]
Value of assets sold on acquisition date, excluded from purchase price	17,700
Insight Pharmaceuticals | Inventory
Business Acquisition [Line Items]
Value of assets sold on acquisition date, excluded from purchase price	600
Insight Pharmaceuticals | Property, plant and equipment
Business Acquisition [Line Items]
Value of assets sold on acquisition date, excluded from purchase price	$ 200
Hydralyte
Business Acquisition [Line Items]
Goodwill						$ 1,224
Non-amortizable intangible assets						$ 73,580
Scenario, Forecast | DenTek Oral Care, Inc.
Business Acquisition [Line Items]
Purchase price of acquisition		$ 0

Acquisitions (Allocation of Ass

Acquisitions (Allocation of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015	Sep. 03, 2014	Apr. 30, 2014
Purchase Price
Goodwill	$ 282,679	$ 290,651
Insight Pharmaceuticals
Purchase Price
Cash acquired			$ 3,507
Accounts receivable			26,012
Inventories			23,456
Deferred income tax assets - current			1,032
Prepaids and other current assets			1,341
Property, plant and equipment			2,308
Goodwill			96,323
Intangible assets			724,374
Total assets acquired			878,353
Accounts payable			16,079
Accrued expenses			8,539
Deferred income tax liabilities - long term			107,799
Total liabilities assumed			132,417
Net assets acquired			$ 745,936
Hydralyte
Purchase Price
Inventories				$ 1,970
Property, plant and equipment				1,267
Goodwill				1,224
Intangible assets				73,580
Total assets acquired				78,041
Accrued expenses				38
Other long-term liabilities				12
Total liabilities assumed				50
Net assets acquired				$ 77,991

Acquisitions (Pro Forma) (Detai

Acquisitions (Pro Forma) (Details) - Insight Pharmaceuticals $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2014USD ($)$ / shares
Business Acquisition, Pro Forma Information [Abstract]
Revenues | $	$ 593,171
Net income | $	$ 62,688
Earnings per share:
Basic (in dollars per share) | $ / shares	$ 1.20
Diluted (in dollars per share) | $ / shares	$ 1.19

Accounts Receivable (Details)

Accounts Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 96,072	$ 97,764
Less allowances for discounts, returns and uncollectible accounts	(10,987)	(9,906)
Accounts receivable, net	85,085	87,858
Trade accounts receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	94,636	95,411
Other receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 1,436	$ 2,353

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 8,097	$ 7,588
Finished goods	72,574	66,412
Inventories	80,671	74,000
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 2,600	$ 4,100

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015
Components of Property and Equipment
Property and equipment, gross	$ 27,705		$ 27,705		$ 25,700
Accumulated depreciation	(15,403)		(15,403)		(11,956)
Property and equipment, net	12,302		12,302		13,744
Depreciation	1,200	$ 1,000	3,700	$ 2,600
Machinery
Components of Property and Equipment
Property and equipment, gross	4,085		4,085		4,743
Computer equipment
Components of Property and Equipment
Property and equipment, gross	13,843		13,843		11,339
Furniture and fixtures
Components of Property and Equipment
Property and equipment, gross	2,406		2,406		2,484
Leasehold improvements
Components of Property and Equipment
Property and equipment, gross	$ 7,371		$ 7,371		$ 7,134

Goodwill (Details)

Goodwill (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2015USD ($)
Goodwill [Roll Forward]
Balance — March 31, 2015	$ 290,651
Adjustments	(6,932)
Effects of foreign currency exchange rates	(1,040)
Balance — December 31, 2015	282,679
North American OTC Healthcare
Goodwill [Roll Forward]
Balance — March 31, 2015	263,411
Adjustments	(6,932)
Effects of foreign currency exchange rates	0
Balance — December 31, 2015	256,479
International OTC Healthcare
Goodwill [Roll Forward]
Balance — March 31, 2015	20,440
Adjustments	0
Effects of foreign currency exchange rates	(1,040)
Balance — December 31, 2015	19,400
Household Cleaning
Goodwill [Roll Forward]
Balance — March 31, 2015	6,800
Adjustments	0
Effects of foreign currency exchange rates	0
Balance — December 31, 2015	$ 6,800

Goodwill (Narrative) (Details)

Goodwill (Narrative) (Details)	1 Months Ended	3 Months Ended		9 Months Ended	12 Months Ended
	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)	Mar. 31, 2015USD ($)business	Sep. 03, 2014USD ($)	Apr. 30, 2014USD ($)
Goodwill [Line Items]
Number of acquisitions | business					2
Goodwill		$ 282,679,000		$ 282,679,000	$ 290,651,000
Increase (decrease) in goodwill				(6,932,000)
Goodwill impairment				$ 0
Insight Pharmaceuticals
Goodwill [Line Items]
Goodwill						$ 96,323,000
Increase (decrease) in goodwill		$ (7,200,000)	$ 300,000
Hydralyte
Goodwill [Line Items]
Goodwill							$ 1,224,000
Comet Brand
Goodwill [Line Items]
Gain on sale of intangibles	$ 1,300,000

Intangible Assets (Schedule of

Intangible Assets (Schedule of Reconciliation of Activity Affecting Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2015	Mar. 31, 2015
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	$ 1,869,021	$ 1,869,021
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite Lived Trademarks, accumulated amortization, beginning balance		96,770
Accumulated amortization, additions	4,800	13,745
Accumulated amortization, effects of foreign exchange rates		(9)
Finite Lived Trademarks, accumulated amortization, ending balance	110,506	110,506
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance		2,231,470
Totals, effects of foreign currency exchange rate		(4,453)
Totals, gross, ending balance	2,227,017	2,227,017
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	247,490	247,490
Intangible Assets, Net [Abstract]
Intangible assets, net	2,116,511	2,116,511	$ 2,134,700
North American OTC Healthcare
Intangible Assets, Net [Abstract]
Intangible assets, net	1,900,263	1,900,263
International OTC Healthcare
Intangible Assets, Net [Abstract]
Intangible assets, net	82,862	82,862
Household Cleaning
Intangible Assets, Net [Abstract]
Intangible assets, net	133,386	133,386
Finite Lived Trademarks
Finite-Lived Intangible Assets, Gross [Abstract]
Finite Lived Trademarks, beginning balance		358,066
Finite Lived Trademarks, effects of foreign currency exchange rate		(70)
Finite Lived Trademarks, ending balance	357,996	357,996
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite Lived Trademarks, accumulated amortization, beginning balance		96,770
Accumulated amortization, additions		13,745
Accumulated amortization, effects of foreign exchange rates		(9)
Finite Lived Trademarks, accumulated amortization, ending balance	110,506	110,506
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	247,490	247,490
Finite Lived Trademarks | North American OTC Healthcare
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	223,272	223,272
Finite Lived Trademarks | International OTC Healthcare
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	1,104	1,104
Finite Lived Trademarks | Household Cleaning
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	23,114	23,114
Indefinite Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		1,873,404
Indefinite Lived Trademarks, effects of foreign currency exchange rate		(4,383)
Indefinite Lived Trademarks, ending balance	1,869,021	1,869,021
Indefinite Lived Trademarks | North American OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	1,676,991	1,676,991
Indefinite Lived Trademarks | International OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	81,758	81,758
Indefinite Lived Trademarks | Household Cleaning
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	$ 110,272	$ 110,272

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) $ in Thousands	Sep. 03, 2014USD ($)brand	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2015USD ($)	Mar. 31, 2015business	Apr. 30, 2014USD ($)
Finite-Lived Intangible Assets [Line Items]
Number of acquisitions | business					2
Weighted average remaining life for finite-lived intangible assets				13 years 10 months 9 days
Amortization expense			$ 4,800	$ 13,745
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives				10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives				30 years
Insight Pharmaceuticals
Finite-Lived Intangible Assets [Line Items]
Intangible assets	$ 724,374
Number of brands sold | brand	1
Weighted average remaining life for finite-lived intangible assets				14 years 10 months
Hydralyte
Finite-Lived Intangible Assets [Line Items]
Intangible assets						$ 73,580
One Brand Acquired from Insight Subsequently Sold [Member] | Insight Pharmaceuticals
Finite-Lived Intangible Assets [Line Items]
Intangible assets	$ 17,700
Comet Brand
Finite-Lived Intangible Assets [Line Items]
Sale of marketing rights		$ 10,000
Gain on sale of marketing rights		1,300
Proceeds from sale of marketing rights, quarterly amount		$ 1,000

Intangible Assets (Expected Amo

Intangible Assets (Expected Amortization Expense) (Details) $ in Thousands	Dec. 31, 2015USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2016 (Remaining three months ending March 31, 2016)	$ 4,466
2,017	17,863
2,018	17,863
2,019	17,863
2,020	17,863
Thereafter	171,572
Intangible assets, net	$ 247,490

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued marketing costs	$ 24,757	$ 16,903
Accrued compensation costs	6,837	8,840
Accrued broker commissions	1,231	1,134
Income taxes payable	3,456	2,642
Accrued professional fees	2,229	2,769
Deferred rent	825	1,021
Accrued production costs	5,303	5,610
Accrued lease termination costs	544	669
Other accrued liabilities	3,641	1,360
Total other accrued liabilities	$ 48,823	$ 40,948

Long-Term Debt (2012 Senior Not

Long-Term Debt (2012 Senior Notes) (Details) - USD ($)	Dec. 31, 2015	Mar. 31, 2015	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Percentage of subsidiary owned			100.00%	100.00%
Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount				$ 250,000,000
Debt instrument, stated interest rate (percent)	8.125%	8.125%		8.125%
Debt issuance costs capitalized				$ 12,600,000

Long-Term Debt (2012 Term Loan

Long-Term Debt (2012 Term Loan and 2012 ABL Revolver) (Details) - USD ($)	Jun. 09, 2015	May. 08, 2015	Sep. 03, 2014	Feb. 21, 2013	Jan. 31, 2012	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 17, 2013
Debt Instrument [Line Items]
Percentage of subsidiary owned					100.00%						100.00%
Loss on extinguishment of debt						$ 0	$ 0		$ 451,000	$ 0
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, maturity term					5 years
Line of credit facility, maximum borrowing capacity					$ 50,000,000	135,000,000			135,000,000
Line of credit facility, increase in borrowing capacity						$ 85,000,000			$ 85,000,000
Debt instrument, interest rate, increase/(decrease) (percent)									(0.25%)
Debt instrument, average interest rate during period (percent)									2.10%
Line of credit facility, commitment fee percentage			0.50%
Line of credit facility, conditional commitment fee percentage			0.375%
2012 ABL Revolver | Revolving Credit Facility | LIBOR
Debt Instrument [Line Items]
Debt instrument, variable rate (percent)			1.75%
2012 ABL Revolver | Revolving Credit Facility | LIBOR | Minimum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (percent)			2.00%
2012 ABL Revolver | Revolving Credit Facility | LIBOR | Maximum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (percent)			2.25%
2012 ABL Revolver | Revolving Credit Facility | Base Rate
Debt Instrument [Line Items]
Debt instrument, variable rate (percent)			0.75%
2012 ABL Revolver | Revolving Credit Facility | Base Rate | Minimum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (percent)			1.00%
2012 ABL Revolver | Revolving Credit Facility | Base Rate | Maximum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (percent)			1.25%
2012 ABL Revolver | Revolving Credit Facility | Base Rate | Federal Funds Effective Swap Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (percent)			0.50%
2012 ABL Revolver | Revolving Credit Facility | Base Rate | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (percent)			1.00%
Term Loan and ABL Revolver 2012
Debt Instrument [Line Items]
Debt issuance costs capitalized					20,600,000
2012 ABL Revolver Amendment 3 | Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, increase in borrowing capacity			$ 40,000,000
Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount					$ 660,000,000
Debt instrument, maturity term					7 years
Debt instrument, discount, percentage					1.50%
Proceeds from issuance of long-term debt					$ 650,100,000
Debt instrument, average interest rate during period (percent)									4.50%
Debt instrument, quarterly payment, percent of original principal amount (percent)					0.25%
Term Loans | 2012 Term Loan | LIBOR | Minimum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)					0.75%
Term Loans | 2012 Term Loan | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (percent)					1.75%
Term Loans | 2012 Term Loan | Base Rate | Federal Funds Effective Swap Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (percent)					0.50%
Term Loans | 2012 Term Loan | Base Rate | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (percent)					1.00%
Term Loans | Amendment 1, 2012 Term Loan
Debt Instrument [Line Items]
Loss on extinguishment of debt								$ 1,400,000
Term Loans | Amendment 1, 2012 Term Loan | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)				2.75%
Debt instrument, reference rate floor (percent)				1.00%
Term Loans | Amendment 1, 2012 Term Loan | Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)				2.00%
Term Loans | Amendment 2, 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)			1.00%
Term Loans | Amendment 2, 2012 Term Loan | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)			3.125%
Term Loans | Amendment 2, 2012 Term Loan | Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)			2.00%
2012 ABL Revolver | Amendment 4, 2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, maturity term	5 years
Line of credit facility, increase in borrowing capacity	$ 35,000,000
Term B-2 | Amendment 2, 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount			$ 720,000,000
Term B-2 | Amendment 2, 2012 Term Loan | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)			3.50%
Debt instrument, reference rate floor (percent)			1.00%
Debt instrument, step down interest rate (percent)			3.25%
Term B-2 | Amendment 2, 2012 Term Loan | Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)			2.00%
Term B-2 | Amendment 3, 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount		$ 645,000,000
Loans Payable, Term B-3 | Amendment 3, 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount		$ 852,500,000
Debt instrument, quarterly payment, percent of original principal amount (percent)		0.25%
Loans Payable, Term B-3 | Amendment 3, 2012 Term Loan | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)		2.75%
Debt instrument, stated interest rate, minimum (percent)		0.75%
Loans Payable, Term B-3 | Amendment 3, 2012 Term Loan | Base Rate
Debt Instrument [Line Items]
Debt instrument, stated interest rate, minimum (percent)		1.75%
Loans Payable, Term B-1 | Amendment 3, 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount		$ 207,500,000

Long-Term Debt (2013 Senior Not

Long-Term Debt (2013 Senior Notes) (Details) - USD ($)	Dec. 31, 2015	Mar. 31, 2015	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Percentage of subsidiary owned			100.00%	100.00%
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount			$ 400,000,000
Debt instrument, stated interest rate (percent)	5.375%	5.375%	5.375%
Debt issuance costs capitalized			$ 7,200,000

Long-Term Debt (Redemptions and

Long-Term Debt (Redemptions and Restrictions) (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Debt Instrument [Line Items]
Decrease in other long-term assets	$ (1,352)	$ (1,165)
Debt instrument, unamortized discount	30,468	32,327
Adjustments for new accounting pronouncement
Debt Instrument [Line Items]
Decrease in other long-term assets		$ 27,400
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Remaining borrowing capacity	115,400
Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Unamortized debt issuance expense and discount	$ 7,600
Senior Notes | 2012 Senior Notes | Prior to February 1, 2016
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	100.00%
Senior Notes | 2012 Senior Notes | Prior to February 1, 2015
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	108.125%
Debt instrument, percentage of principal amount eligible for redemption	35.00%
Senior Notes | 2012 Senior Notes | Upon Change in Control
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	101.00%
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	101.00%
Unamortized debt issuance expense and discount	$ 5,700
Senior Notes | 2013 Senior Notes | Prior to December 15, 2016
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	100.00%
Debt instrument, percentage of principal amount eligible for redemption	35.00%
Senior Notes | 2013 Senior Notes | On Or After December 15, 2016
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	105.375%
Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Unamortized debt issuance expense and discount	$ 17,200

Long-Term Debt (Schedule of Lon

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,477,500	$ 1,593,600
Current portion of long-term debt	0	0
Principal amount	1,477,500	1,593,600
Less: unamortized debt costs	(30,468)	(32,327)
Long-term debt, net	1,447,032	1,561,273
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 0	$ 66,100
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	5.375%	5.375%	5.375%
Long-term debt, gross	$ 400,000	$ 400,000
Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	8.125%	8.125%		8.125%
Long-term debt, gross	$ 250,000	$ 250,000
Loans Payable, Term B-3 | 2012 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	$ 827,500	$ 877,500
Loans Payable, Term B-3 | 2012 Senior Notes | Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)	1.75%	1.75%
Loans Payable, Term B-3 | 2012 Senior Notes | LIBOR
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)	0.75%	0.75%

Long-Term Debt (Maturities of L

Long-Term Debt (Maturities of Long-term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Debt Disclosure [Abstract]
2016 (remaining three months ending March 31, 2016)	$ 0
2,017	0
2,018	0
2,019	6,969
2,020	258,525
Thereafter	1,212,006
Long-term debt, gross	$ 1,477,500	$ 1,593,600

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Millions	Dec. 31, 2015	Mar. 31, 2015
2012 ABL Revolver | Market Value | Fair Value, Inputs, Level 2 | Revolving Credit Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	$ 0	$ 65.7
2012 ABL Revolver | Carrying Value | Revolving Credit Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	0	66.1
Senior Notes | 2013 Senior Notes | Market Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	384	405
Senior Notes | 2013 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	400	400
Senior Notes | 2012 Senior Notes | Market Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	257.5	268.1
Senior Notes | 2012 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	250	250
Term Loans | 2012 Term Loan | Market Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	822.3	880.5
Term Loans | 2012 Term Loan | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	$ 827.5	$ 877.5

Stockholders' Equity (Details)

Stockholders' Equity (Details)	3 Months Ended		9 Months Ended
	Dec. 31, 2015vote$ / sharesshares	Dec. 31, 2014shares	Dec. 31, 2015vote$ / sharesshares	Dec. 31, 2014$ / sharesshares	Mar. 31, 2015$ / sharesshares
Class of Stock [Line Items]
Common stock, shares authorized (shares) | shares	250,000,000		250,000,000		250,000,000
Common stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares authorized (shares) | shares	5,000,000		5,000,000		5,000,000
Preferred stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01		$ 0.01
Voting rights, number of votes per common share owned | vote	1		1
Restricted Shares
Class of Stock [Line Items]
Restricted stock repurchased during period (shares) | shares	0	781	39,429	48,445
Restricted stock acquired, average cost per share (in USD per share) | $ / shares			$ 41.66	$ 33.66

Accumulated Other Comprehensi66

Accumulated Other Comprehensive Loss (Components of AOCI) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Cumulative translation adjustment	$ (29,974)	$ (23,412)
Accumulated other comprehensive loss, net of tax	$ (29,974)	$ (23,412)

(Earnings Per Share) (Details)

(Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Numerator
Net income	$ 27,995	$ 21,293	$ 85,971	$ 54,488
Denominator
Denominator for basic earnings per share — weighted average shares outstanding	52,824	52,278	52,727	52,110
Dilutive effect of unvested restricted stock units and options issued to employees and directors	379	452	379	512
Denominator for diluted earnings per share (in shares)	53,203	52,730	53,106	52,622
Earnings per Common Share:
Basic net earnings per share (in USD per share)	$ 0.53	$ 0.41	$ 1.63	$ 1.05
Diluted net earnings per share (in USD per share)	$ 0.53	$ 0.40	$ 1.62	$ 1.04

Earnings Per Share (Antidilutiv

Earnings Per Share (Antidilutive Securities) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares (less than $0.1 million and $0.3 million)	0.2	0.3	0.1	0.3

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) $ / shares in Units, $ in Millions

Oct. 28, 2015$ / sharesshares

Aug. 04, 2015shares

Jul. 01, 2015$ / sharesshares

Jun. 01, 2015USD ($)

May. 11, 2015$ / sharesshares

Apr. 22, 2015shares

May. 31, 2014shares

Jun. 30, 2014shares

Dec. 31, 2015USD ($)shares

Dec. 31, 2014USD ($)

Dec. 31, 2015USD ($)$ / sharesshares

Dec. 31, 2014USD ($)$ / sharesshares

Share-based Compensation, Aggregate Disclosures:

Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan (in shares)

5,000,000

5,000,000

Share-based compensation costs charged against income | $

$ 2.1

$ 1.5

$ 7.1

$ 4.9

Tax benefit recognized from share-based compensation expense | $

0.7

$ 0.6

$ 2.5

$ 1.8

Stock options granted (in shares)

208,200

307,500

Exercise price of granted awards (in USD per share) | $ / shares

$ 42.13

$ 33.50

Options, Additional Disclosures:

Options granted, weighted-average grant-date fair value (in USD per share) | $ / shares

$ 17.24

$ 15.93

Options exercised, aggregate intrinsic value | $

$ 8.4

Unrecognized compensation costs related to nonvested awards | $

$ 11.6

$ 11.6

Unrecognized compensation costs related to nonvested awards, weighted average period for recognition

1 year 1 month 12 days

Total fair value of vested shares | $

$ 6.6

$ 4.3

Cash received from exercise of stock options | $

6.6

3.7

Tax benefit realized from exercise of stock options | $

$ 2.1

$ 1.9

Shares available for issuance under the Plan

2,600,000

2,600,000

Restricted Stock Units (RSUs)

Share-based Compensation, Aggregate Disclosures:

Granted in period (in shares)

2,075

2,841

185,904

266,100

104,400

Award vesting period

3 years

Restricted Shares

Period following director's term in which RSUs may be settled

6 months

Granted, weighted-average grant-date fair value (in USD per share) | $ / shares

$ 42.41

$ 33.30

Restricted Stock Units (RSUs) | Share-based compensation award, tranche 1

Share-based Compensation, Aggregate Disclosures:

Granted in period (in shares)

163,404

Award vesting period

3 years

Restricted Stock Units (RSUs) | Share-based compensation award, tranche 2

Share-based Compensation, Aggregate Disclosures:

Granted in period (in shares)

22,500

Award vesting period

3 years

Annual award vesting percentage

33.30%

Stock Options

Share-based Compensation, Aggregate Disclosures:

Granted in period (in shares)

13,861

Stock options granted (in shares)

186,302

Award vesting period

3 years

3 years

Annual award vesting percentage

33.30%

33.30%

Term from grant date, exercisable

10 years

10 years

Exercise price of granted awards (in USD per share) | $ / shares

$ 46.58

$ 41.44

Stock Options | Minimum

Share-based Compensation, Aggregate Disclosures:

Award vesting period

3 years

Stock Options | Maximum

Share-based Compensation, Aggregate Disclosures:

Award vesting period

5 years

Options, Additional Disclosures:

Award exercisability period, from date of grant

10 years

Restricted Shares

Restricted Shares

Granted, weighted-average grant-date fair value (in USD per share) | $ / shares

$ 42.41

$ 33.30

Restricted Shares | Minimum

Share-based Compensation, Aggregate Disclosures:

Award vesting period

3 years

Restricted Shares | Maximum

Share-based Compensation, Aggregate Disclosures:

Award vesting period

5 years

President and CEO

Share-based Compensation, Aggregate Disclosures:

Accelerated share-based compensation expense | $

$ 0.8

Granted in period (in shares)

57,924

Chief Financial Officer | Restricted Stock Units (RSUs)

Share-based Compensation, Aggregate Disclosures:

Granted in period (in shares)

6,612

Award vesting period

3 years

Chief Financial Officer | Stock Options

Share-based Compensation, Aggregate Disclosures:

Stock options granted (in shares)

8,079

Award vesting period

3 years

Annual award vesting percentage

33.30%

Term from grant date, exercisable

10 years

Exercise price of granted awards (in USD per share) | $ / shares

$ 50.42

Employee | Restricted Shares

Share-based Compensation, Aggregate Disclosures:

Award vesting period

3 years

Director | Restricted Stock Units (RSUs)

Share-based Compensation, Aggregate Disclosures:

Granted in period (in shares)

362

Restricted Shares

Number of common shares into which each RSU may be converted (in shares)

1

Director | Restricted Shares

Share-based Compensation, Aggregate Disclosures:

Award vesting period

1 year

2005 Long-Term Incentive Plan

Share-based Compensation, Aggregate Disclosures:

Number of additional shares authorized

1,800,000

Maximum number of shares per participant, 12 month period

1,000,000

2,500,000

Extension of plan term

10 years

Share-Based Compensation (Restr

Share-Based Compensation (Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) - $ / shares	Aug. 04, 2015	Jul. 01, 2015	May. 11, 2015	Dec. 31, 2015	Dec. 31, 2014
Shares
Outstanding, beginning of period (in shares)				362,300	437,500
Granted (in shares)	2,075	2,841	185,904	266,100	104,400
Vested and issued (in shares)				(153,600)	(122,800)
Forfeited (in shares)				(1,400)	(21,300)
Outstanding, end of period (in shares)				473,400	397,800
Vested, end of period (in shares)				69,800	76,600
Weighted- Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)				$ 22.74	$ 16.76
Granted, weighted-average grant-date fair value (in USD per share)				42.41	33.30
Vested and issued, weighted-average grant-date fair value (in USD per share)				18.16	13.62
Forfeited, weighted-average grant-date fair value (in USD per share)				33.50	20.77
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)				35.25	21.86
Vested, end of period, weighted-average grant-date fair value (in USD per share)				$ 14.76	$ 11.62

Share-Based Compensation (Stock

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) - Stock Options - USD ($)	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	40.20%	47.30%
Expected dividends	$ 0	$ 0
Expected term in years	6 years	6 years
Risk-free rate	1.70%	2.20%

Share-Based Compensation (Sto72

Share-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Shares
Outstanding, beginning of period (in shares)	871,200	994,900
Granted (in shares)	208,200	307,500
Exercised (in shares)	(336,900)	(363,400)
Forfeited or expired (in shares)	(2,100)	(47,500)
Outstanding, end of period (in shares)	740,400	891,500
Exercisable, end of period (in shares)	313,500	335,100
Weighted- Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 23.40	$ 15.24
Granted, weighted-average exercise price (in USD per share)	42.13	33.50
Exercised, weighted-average exercise price (in USD per share)	18.99	10.05
Forfeited or expired, weighted-average exercise price (in USD per share)	38.21	25.76
Outstanding, end of period, weighted-average exercise price (in USD per share)	30.63	23.09
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 21.68	$ 15.01
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	7 years 11 months	7 years 11 months
Exercisable, end of period, weighted-average remaining contractual term	6 years 8 months	6 years 8 months
Outstanding, end of period, aggregate intrinsic value	$ 15,325	$ 10,368
Exercisable, end of period, aggregate intrinsic value	$ 9,341	$ 6,604

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Effective income tax rate (percent)	35.20%	36.50%	35.20%	39.50%
Ownership percentage, subsidiaries	100.00%		100.00%
Net operating loss carryforwards	$ 36.2		$ 36.2
Operating loss carryforwards, limitation on use, annual amount	33.6		33.6
Increase in uncertain tax liability			0.7
Uncertain tax liability	$ 4.1		$ 4.1		$ 3.4

Commitments and Contingencies74

Commitments and Contingencies (Future Minimum Rental Payments) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015
Operating Leased Assets [Line Items]
2016 (Remaining three months ending March 31, 2016)	$ 502		$ 502
2,017	2,000		2,000
2,018	1,934		1,934
2,019	1,926		1,926
2,020	1,757		1,757
Thereafter	817		817
Total future minimum payments due	8,936		8,936		$ 9,957
Less: Sublease rentals	(1,224)		(1,224)		(1,401)
Minimum lease payments, less minimum sublease rentals	7,712		7,712		$ 8,556
Rent expense	400	$ 400	1,200	$ 1,200
Facilities
Operating Leased Assets [Line Items]
2016 (Remaining three months ending March 31, 2016)	455		455
2,017	1,923		1,923
2,018	1,934		1,934
2,019	1,926		1,926
2,020	1,757		1,757
Thereafter	817		817
Total future minimum payments due	8,812		8,812
Equipment
Operating Leased Assets [Line Items]
2016 (Remaining three months ending March 31, 2016)	47		47
2,017	77		77
2,018	0		0
2,019	0		0
2,020	0		0
Thereafter	0		0
Total future minimum payments due	$ 124		$ 124

Commitments and Contingencies75

Commitments and Contingencies (Long-term Supply Agreement) (Details) - Third-party Manufacturing - USD ($) $ in Thousands	Nov. 01, 2009	Dec. 31, 2015
Long-term Purchase Commitment [Line Items]
Supply agreement, term	10 years
2016 (Remaining three months ending March 31, 2016)		$ 266
2,017		1,044
2,018		1,013
2,019		982
2,020		560
Thereafter		0
Total purchase commitment		$ 3,865

Concentrations of Risk (Details

Concentrations of Risk (Details)	3 Months Ended		9 Months Ended
	Dec. 31, 2015manufacturer	Dec. 31, 2014manufacturer	Dec. 31, 2015brandmanufacturercustomer	Dec. 31, 2014brandmanufacturer
Concentration Risk [Line Items]
Number of third-party manufacturers	101	96	101	96
Sales | Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	41.00%	44.30%	42.20%	41.90%
Number of highest selling brands comprising group against which concentration risk is measured | brand			5	5
Sales | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	20.20%	16.50%	19.90%	17.40%
Number of customers exceeding concentration risk benchmark | customer			1
Sales | Customer Concentration Risk | Customer No. 2
Concentration Risk [Line Items]
Concentration risk, percentage	9.50%		9.60%
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			79.80%	80.10%
Number of third-party manufacturers with long-term contracts			47	44
Accounts Receivable | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage			20.90%

Business Segments (Information

Business Segments (Information on Operating and Reportable Segments) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information, Profit (Loss):
Net sales	$ 199,485	$ 196,435	$ 596,034	$ 520,981
Other revenues	710	1,171	2,358	3,596
Revenues	200,195	197,606	598,392	524,577
Cost of sales	83,411	85,861	249,432	228,424
Gross profit	116,784	111,745	348,960	296,153
Advertising and promotion	29,935	30,144	84,250	74,284
Contribution margin	86,849	81,601	264,710	221,869
Other operating expenses	24,206	24,608	69,664	75,555
Operating income	62,643	56,993	195,046	146,314
Other expense	19,462	23,459	62,464	56,305
Income before income taxes	43,181	33,534	132,582	90,009
Provision for income taxes	15,186	12,241	46,611	35,521
Net income	27,995	21,293	85,971	54,488
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	165,050	160,654	486,796	409,767
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	13,812	15,563	43,254	45,157
Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	20,623	20,218	65,984	66,057
Operating Segments
Segment Reporting Information, Profit (Loss):
Net sales	199,713	197,944	598,462	523,917
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	165,278	162,163	489,224	412,703
Other revenues	0	151	14	478
Revenues	165,050	160,805	486,810	410,245
Cost of sales	62,654	63,479	182,279	158,005
Gross profit	102,396	97,326	304,531	252,240
Advertising and promotion	26,472	26,779	74,107	64,573
Contribution margin	75,924	70,547	230,424	187,667
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	13,812	15,563	43,254	45,157
Other revenues	9	4	41	62
Revenues	13,821	15,567	43,295	45,219
Cost of sales	4,965	6,247	16,347	17,926
Gross profit	8,856	9,320	26,948	27,293
Advertising and promotion	2,838	2,776	8,338	8,151
Contribution margin	6,018	6,544	18,610	19,142
Operating Segments | Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	20,623	20,218	65,984	66,057
Other revenues	701	1,016	2,303	3,056
Revenues	21,324	21,234	68,287	69,113
Cost of sales	15,792	16,135	50,806	52,493
Gross profit	5,532	5,099	17,481	16,620
Advertising and promotion	625	589	1,805	1,560
Contribution margin	4,907	4,510	15,676	15,060
Intersegment Eliminations
Segment Reporting Information, Profit (Loss):
Net sales	(228)	(1,509)	(2,428)	(2,936)
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	(228)	(1,509)	(2,428)	(2,936)
Intersegment Eliminations | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	0	0	0	0
Intersegment Eliminations | Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	$ 0	$ 0	$ 0	$ 0

Business Segments (Revenue by P

Business Segments (Revenue by Product) (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)customer	Dec. 31, 2014USD ($)
Revenue from External Customer [Line Items]
Revenues	$ 200,195	$ 197,606	$ 598,392	$ 524,577
Analgesics
Revenue from External Customer [Line Items]
Revenues	30,904	28,844	88,664	84,404
Cough & Cold
Revenue from External Customer [Line Items]
Revenues	34,162	35,758	87,629	90,831
Women's Health
Revenue from External Customer [Line Items]
Revenues	34,398	31,953	102,417	42,616
Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	22,918	24,033	71,449	73,663
Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	24,549	23,597	80,552	74,397
Dermatologicals
Revenue from External Customer [Line Items]
Revenues	20,258	18,233	64,695	49,182
Oral Care
Revenue from External Customer [Line Items]
Revenues	10,122	12,472	30,215	35,782
Other OTC
Revenue from External Customer [Line Items]
Revenues	1,560	1,482	4,484	4,589
Household Cleaning
Revenue from External Customer [Line Items]
Revenues	21,324	21,234	68,287	69,113
Operating Segments | North American OTC Healthcare
Revenue from External Customer [Line Items]
Revenues	165,050	160,805	486,810	410,245
Operating Segments | North American OTC Healthcare | Analgesics
Revenue from External Customer [Line Items]
Revenues	30,454	28,187	86,996	82,290
Operating Segments | North American OTC Healthcare | Cough & Cold
Revenue from External Customer [Line Items]
Revenues	30,466	31,927	74,661	76,741
Operating Segments | North American OTC Healthcare | Women's Health
Revenue from External Customer [Line Items]
Revenues	33,521	31,364	100,036	40,851
Operating Segments | North American OTC Healthcare | Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	17,401	17,365	56,782	58,899
Operating Segments | North American OTC Healthcare | Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	21,927	20,528	71,137	64,086
Operating Segments | North American OTC Healthcare | Dermatologicals
Revenue from External Customer [Line Items]
Revenues	19,734	17,663	63,026	47,383
Operating Segments | North American OTC Healthcare | Oral Care
Revenue from External Customer [Line Items]
Revenues	9,996	12,300	29,706	35,421
Operating Segments | North American OTC Healthcare | Other OTC
Revenue from External Customer [Line Items]
Revenues	1,551	1,471	4,466	4,574
Operating Segments | International OTC Healthcare
Revenue from External Customer [Line Items]
Revenues	13,821	15,567	43,295	45,219
Operating Segments | International OTC Healthcare | Analgesics
Revenue from External Customer [Line Items]
Revenues	450	657	1,668	2,114
Operating Segments | International OTC Healthcare | Cough & Cold
Revenue from External Customer [Line Items]
Revenues	3,696	3,831	12,968	14,090
Operating Segments | International OTC Healthcare | Women's Health
Revenue from External Customer [Line Items]
Revenues	877	589	2,381	1,765
Operating Segments | International OTC Healthcare | Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	5,517	6,668	14,667	14,764
Operating Segments | International OTC Healthcare | Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	2,622	3,069	9,415	10,311
Operating Segments | International OTC Healthcare | Dermatologicals
Revenue from External Customer [Line Items]
Revenues	524	570	1,669	1,799
Operating Segments | International OTC Healthcare | Oral Care
Revenue from External Customer [Line Items]
Revenues	126	172	509	361
Operating Segments | International OTC Healthcare | Other OTC
Revenue from External Customer [Line Items]
Revenues	9	11	18	15
Operating Segments | Household Cleaning
Revenue from External Customer [Line Items]
Revenues	21,324	21,234	68,287	69,113
Operating Segments | Household Cleaning | Analgesics
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Operating Segments | Household Cleaning | Cough & Cold
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Operating Segments | Household Cleaning | Women's Health
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Operating Segments | Household Cleaning | Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Operating Segments | Household Cleaning | Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Operating Segments | Household Cleaning | Dermatologicals
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Operating Segments | Household Cleaning | Oral Care
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Operating Segments | Household Cleaning | Other OTC
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Operating Segments | Household Cleaning | Household Cleaning
Revenue from External Customer [Line Items]
Revenues	$ 21,324	$ 21,234	$ 68,287	$ 69,113
Sales | United States | Geographic Concentration Risk
Revenue from External Customer [Line Items]
Number of customers exceeding threshold | customer			0
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	87.80%	85.90%	86.90%	84.40%
Sales | CANADA | Geographic Concentration Risk
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	5.00%	5.10%	5.20%	6.10%
Sales | AUSTRALIA | Geographic Concentration Risk
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	5.00%	7.20%	5.90%	7.50%
Goodwill and Intangible Assets | United States | Geographic Concentration Risk
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage			95.70%
Goodwill and Intangible Assets | AUSTRALIA | Geographic Concentration Risk
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage			4.30%

Business Segments (Assets by Se

Business Segments (Assets by Segment) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 282,679	$ 290,651
Indefinite-lived intangibles	1,869,021
Finite-lived intangibles	247,490
Intangible assets, net	2,116,511	2,134,700
Intangible assets, net (including goodwill)	2,399,190
Finite Lived Trademarks
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived intangibles	247,490
Indefinite Lived Trademarks
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived intangibles	1,869,021	1,873,404
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	256,479	263,411
Intangible assets, net	1,900,263
Intangible assets, net (including goodwill)	2,156,742
North American OTC Healthcare | Finite Lived Trademarks
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived intangibles	223,272
North American OTC Healthcare | Indefinite Lived Trademarks
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived intangibles	1,676,991
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	19,400	20,440
Intangible assets, net	82,862
Intangible assets, net (including goodwill)	102,262
International OTC Healthcare | Finite Lived Trademarks
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived intangibles	1,104
International OTC Healthcare | Indefinite Lived Trademarks
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived intangibles	81,758
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	6,800	$ 6,800
Intangible assets, net	133,386
Intangible assets, net (including goodwill)	140,186
Household Cleaning | Finite Lived Trademarks
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived intangibles	23,114
Household Cleaning | Indefinite Lived Trademarks
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived intangibles	$ 110,272

Condensed Consolidating Finan80

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Revenues
Net sales	$ 199,485	$ 196,435	$ 596,034	$ 520,981
Other revenues	710	1,171	2,358	3,596
Revenues	200,195	197,606	598,392	524,577
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	83,411	85,861	249,432	228,424
Gross profit	116,784	111,745	348,960	296,153
Operating Expenses
Advertising and promotion	29,935	30,144	84,250	74,284
General and administrative	18,135	19,454	52,186	63,588
Depreciation and amortization	6,071	5,154	17,478	11,967
Total operating expenses	54,141	54,752	153,914	149,839
Operating income	62,643	56,993	195,046	146,314
Other (income) expense
Interest income	(31)	(20)	(91)	(67)
Interest expense	19,493	24,612	62,104	57,505
Loss on extinguishment of debt	0	0	451	0
Gain on sale of asset	0	(1,133)	0	(1,133)
Equity in (income) loss of subsidiaries	0	0	0	0
Total other expense	19,462	23,459	62,464	56,305
Income before income taxes	43,181	33,534	132,582	90,009
Provision for income taxes	15,186	12,241	46,611	35,521
Net income	27,995	21,293	85,971	54,488
Comprehensive income, net of tax:
Currency translation adjustments	4,922	(8,779)	(6,562)	(16,883)
Total other comprehensive loss	4,922	(8,779)	(6,562)	(16,883)
Comprehensive income	32,917	12,514	79,409	37,605
Prestige Brands Holdings, Inc.
Revenues
Net sales	0	0	0	0
Other revenues	0	0	0	0
Revenues	0	0	0	0
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	0	0	0	0
Gross profit	0	0	0	0
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	1,370	1,408	3,884	3,662
Depreciation and amortization	1,013	869	3,032	2,381
Total operating expenses	2,383	2,277	6,916	6,043
Operating income	(2,383)	(2,277)	(6,916)	(6,043)
Other (income) expense
Interest income	(12,141)	(12,226)	(36,351)	(36,604)
Interest expense	8,602	8,611	26,056	25,788
Loss on extinguishment of debt			0
Gain on sale of asset		0		0
Equity in (income) loss of subsidiaries	(27,711)	(20,462)	(84,458)	(53,718)
Total other expense	(31,250)	(24,077)	(94,753)	(64,534)
Income before income taxes	28,867	21,800	87,837	58,491
Provision for income taxes	872	507	1,866	4,003
Net income	27,995	21,293	85,971	54,488
Comprehensive income, net of tax:
Currency translation adjustments	4,922	(8,779)	(6,562)	(16,883)
Total other comprehensive loss	4,922	(8,779)	(6,562)	(16,883)
Comprehensive income	32,917	12,514	79,409	37,605
Prestige Brands, Inc., the issuer or the borrower
Revenues
Net sales	27,598	27,937	83,438	80,514
Other revenues	98	83	273	308
Revenues	27,696	28,020	83,711	80,822
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	11,796	10,296	33,105	30,170
Gross profit	15,900	17,724	50,606	50,652
Operating Expenses
Advertising and promotion	1,881	2,175	7,602	7,563
General and administrative	1,789	1,879	5,644	7,793
Depreciation and amortization	151	156	444	446
Total operating expenses	3,821	4,210	13,690	15,802
Operating income	12,079	13,514	36,916	34,850
Other (income) expense
Interest income	(21,569)	(21,602)	(64,584)	(52,546)
Interest expense	19,443	24,612	61,654	57,505
Loss on extinguishment of debt			451
Gain on sale of asset		0		0
Equity in (income) loss of subsidiaries	(15,898)	(12,977)	(52,599)	(33,700)
Total other expense	(18,024)	(9,967)	(55,078)	(28,741)
Income before income taxes	30,103	23,481	91,994	63,591
Provision for income taxes	4,950	3,782	13,867	10,761
Net income	25,153	19,699	78,127	52,830
Comprehensive income, net of tax:
Currency translation adjustments	4,922	(8,779)	(6,562)	(16,883)
Total other comprehensive loss	4,922	(8,779)	(6,562)	(16,883)
Comprehensive income	30,075	10,920	71,565	35,947
Combined Subsidiary Guarantors
Revenues
Net sales	159,783	155,733	477,079	402,967
Other revenues	700	1,166	2,317	3,506
Revenues	160,483	156,899	479,396	406,473
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	68,148	71,891	206,646	187,218
Gross profit	92,335	85,008	272,750	219,255
Operating Expenses
Advertising and promotion	25,251	25,202	68,412	58,579
General and administrative	13,463	13,760	38,326	43,079
Depreciation and amortization	4,794	3,864	13,686	8,682
Total operating expenses	43,508	42,826	120,424	110,340
Operating income	48,827	42,182	152,326	108,915
Other (income) expense
Interest income	(1,124)	(1,278)	(3,513)	(3,800)
Interest expense	25,255	25,212	75,604	63,350
Loss on extinguishment of debt			0
Gain on sale of asset		(1,133)		(1,133)
Equity in (income) loss of subsidiaries	(2,033)	(1,654)	(6,868)	(2,565)
Total other expense	22,098	21,147	65,223	55,852
Income before income taxes	26,729	21,035	87,103	53,063
Provision for income taxes	8,582	6,977	28,243	18,179
Net income	18,147	14,058	58,860	34,884
Comprehensive income, net of tax:
Currency translation adjustments	4,922	(8,779)	(6,562)	(16,883)
Total other comprehensive loss	4,922	(8,779)	(6,562)	(16,883)
Comprehensive income	23,069	5,279	52,298	18,001
Combined Non-Guarantor Subsidiaries
Revenues
Net sales	12,332	14,273	37,945	40,436
Other revenues	356	266	1,397	1,104
Revenues	12,688	14,539	39,342	41,540
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	4,448	5,208	13,808	14,998
Gross profit	8,240	9,331	25,534	26,542
Operating Expenses
Advertising and promotion	2,803	2,767	8,236	8,142
General and administrative	1,513	2,407	4,332	9,054
Depreciation and amortization	113	265	316	458
Total operating expenses	4,429	5,439	12,884	17,654
Operating income	3,811	3,892	12,650	8,888
Other (income) expense
Interest income	(128)	(15)	(366)	(55)
Interest expense	1,124	1,278	3,513	3,800
Loss on extinguishment of debt			0
Gain on sale of asset		0		0
Equity in (income) loss of subsidiaries	0	0	0	0
Total other expense	996	1,263	3,147	3,745
Income before income taxes	2,815	2,629	9,503	5,143
Provision for income taxes	782	975	2,635	2,578
Net income	2,033	1,654	6,868	2,565
Comprehensive income, net of tax:
Currency translation adjustments	4,922	(8,779)	(6,562)	(16,883)
Total other comprehensive loss	4,922	(8,779)	(6,562)	(16,883)
Comprehensive income	6,955	(7,125)	306	(14,318)
Consolidation, Eliminations
Revenues
Net sales	(228)	(1,508)	(2,428)	(2,936)
Other revenues	(444)	(344)	(1,629)	(1,322)
Revenues	(672)	(1,852)	(4,057)	(4,258)
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	(981)	(1,534)	(4,127)	(3,962)
Gross profit	309	(318)	70	(296)
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	0	0	0	0
Depreciation and amortization	0	0	0	0
Total operating expenses	0	0	0	0
Operating income	309	(318)	70	(296)
Other (income) expense
Interest income	34,931	35,101	104,723	92,938
Interest expense	(34,931)	(35,101)	(104,723)	(92,938)
Loss on extinguishment of debt			0
Gain on sale of asset		0		0
Equity in (income) loss of subsidiaries	45,642	35,093	143,925	89,983
Total other expense	45,642	35,093	143,925	89,983
Income before income taxes	(45,333)	(35,411)	(143,855)	(90,279)
Provision for income taxes	0	0	0	0
Net income	(45,333)	(35,411)	(143,855)	(90,279)
Comprehensive income, net of tax:
Currency translation adjustments	(14,766)	26,337	19,686	50,649
Total other comprehensive loss	(14,766)	26,337	19,686	50,649
Comprehensive income	$ (60,099)	$ (9,074)	$ (124,169)	$ (39,630)

Condensed Consolidating Finan81

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Condensed Financial Statements, Captions [Line Items]
Ownership percentage, subsidiaries	100.00%
Current assets
Cash and cash equivalents	$ 48,973	$ 21,318	$ 21,951	$ 28,331
Accounts receivable, net	85,085	87,858
Inventories	80,671	74,000
Deferred income tax assets	8,406	8,097
Prepaid expenses and other current assets	5,020	10,434
Total current assets	228,155	201,707
Property and equipment, net	12,302	13,744
Goodwill	282,679	290,651
Intangible assets, net	2,116,511	2,134,700
Other long-term assets	1,352	1,165
Intercompany receivables	0	0
Investment in subsidiary	0	0
Total Assets	2,640,999	2,641,967
Current liabilities
Accounts payable	28,539	46,115
Accrued interest payable	9,359	11,974
Other accrued liabilities	48,823	40,948
Total current liabilities	86,721	99,037
Long-term debt
Principal amount	1,477,500	1,593,600
Less unamortized debt costs	(30,468)	(32,327)
Long-term debt, net	1,447,032	1,561,273
Deferred income tax liabilities	383,485	351,569
Other long-term liabilities	2,823	2,464
Intercompany payables	0	0
Total Liabilities	1,920,061	2,014,343
Stockholders' Equity
Common stock	530	525
Additional paid-in capital	442,127	426,584
Treasury stock, at cost	(5,121)	(3,478)
Accumulated other comprehensive loss, net of tax	(29,974)	(23,412)
Retained earnings (accumulated deficit)	313,376	227,405
Total Stockholders' Equity	720,938	627,624
Total Liabilities and Stockholders' Equity	2,640,999	2,641,967
Prestige Brands Holdings, Inc.
Current assets
Cash and cash equivalents	33,752	11,387	14,275	24,644
Accounts receivable, net	0	0
Inventories	0	0
Deferred income tax assets	304	452
Prepaid expenses and other current assets	2,174	5,731
Total current assets	36,230	17,570
Property and equipment, net	9,383	10,726
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	1,231,094	1,210,017
Investment in subsidiary	1,620,683	1,545,575
Total Assets	2,897,390	2,783,888
Current liabilities
Accounts payable	1,952	1,959
Accrued interest payable	0	0
Other accrued liabilities	10,276	10,378
Total current liabilities	12,228	12,337
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	2,164,224	2,143,927
Total Liabilities	2,176,452	2,156,264
Stockholders' Equity
Common stock	530	525
Additional paid-in capital	442,127	426,584
Treasury stock, at cost	(5,121)	(3,478)
Accumulated other comprehensive loss, net of tax	(29,974)	(23,412)
Retained earnings (accumulated deficit)	313,376	227,405
Total Stockholders' Equity	720,938	627,624
Total Liabilities and Stockholders' Equity	2,897,390	2,783,888
Prestige Brands, Inc., the issuer or the borrower
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	13,381	14,539
Inventories	11,186	8,667
Deferred income tax assets	728	674
Prepaid expenses and other current assets	446	141
Total current assets	25,741	24,021
Property and equipment, net	227	175
Goodwill	66,007	66,007
Intangible assets, net	191,923	192,325
Other long-term assets	1,352	1,165
Intercompany receivables	2,523,623	2,607,054
Investment in subsidiary	1,274,571	1,228,535
Total Assets	4,083,444	4,119,282
Current liabilities
Accounts payable	5,668	6,829
Accrued interest payable	9,359	11,974
Other accrued liabilities	2,132	1,153
Total current liabilities	17,159	19,956
Long-term debt
Principal amount	1,477,500	1,593,600
Less unamortized debt costs	(30,468)	(32,327)
Long-term debt, net	1,447,032	1,561,273
Deferred income tax liabilities	59,256	59,038
Other long-term liabilities	0	0
Intercompany payables	1,010,637	1,001,219
Total Liabilities	2,534,084	2,641,486
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	1,280,947	1,280,948
Treasury stock, at cost	0	0
Accumulated other comprehensive loss, net of tax	(29,974)	(23,412)
Retained earnings (accumulated deficit)	298,387	220,260
Total Stockholders' Equity	1,549,360	1,477,796
Total Liabilities and Stockholders' Equity	4,083,444	4,119,282
Combined Subsidiary Guarantors
Current assets
Cash and cash equivalents	0	0	489	0
Accounts receivable, net	64,679	66,523
Inventories	63,466	60,297
Deferred income tax assets	6,921	6,497
Prepaid expenses and other current assets	1,165	3,804
Total current assets	136,231	137,121
Property and equipment, net	2,085	2,207
Goodwill	197,272	204,205
Intangible assets, net	1,841,558	1,854,798
Other long-term assets	0	0
Intercompany receivables	960,672	668,169
Investment in subsidiary	68,658	65,564
Total Assets	3,206,476	2,932,064
Current liabilities
Accounts payable	18,372	32,898
Accrued interest payable	0	0
Other accrued liabilities	31,852	25,795
Total current liabilities	50,224	58,693
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	324,211	292,504
Other long-term liabilities	2,664	2,293
Intercompany payables	1,478,338	1,279,833
Total Liabilities	1,855,437	1,633,323
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	1,131,578	1,131,578
Treasury stock, at cost	0	0
Accumulated other comprehensive loss, net of tax	(29,974)	(23,412)
Retained earnings (accumulated deficit)	249,435	190,575
Total Stockholders' Equity	1,351,039	1,298,741
Total Liabilities and Stockholders' Equity	3,206,476	2,932,064
Combined Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	15,221	9,931	7,187	3,687
Accounts receivable, net	7,025	6,796
Inventories	7,095	6,182
Deferred income tax assets	453	474
Prepaid expenses and other current assets	1,235	758
Total current assets	31,029	24,141
Property and equipment, net	607	636
Goodwill	19,400	20,439
Intangible assets, net	83,030	87,577
Other long-term assets	0	0
Intercompany receivables	10,958	8,764
Investment in subsidiary	0	0
Total Assets	145,024	141,557
Current liabilities
Accounts payable	2,547	4,429
Accrued interest payable	0	0
Other accrued liabilities	4,563	3,622
Total current liabilities	7,110	8,051
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	18	27
Other long-term liabilities	159	171
Intercompany payables	73,148	69,025
Total Liabilities	80,435	77,274
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	74,031	74,031
Treasury stock, at cost	0	0
Accumulated other comprehensive loss, net of tax	(29,974)	(23,412)
Retained earnings (accumulated deficit)	20,532	13,664
Total Stockholders' Equity	64,589	64,283
Total Liabilities and Stockholders' Equity	145,024	141,557
Consolidation, Eliminations
Current assets
Cash and cash equivalents	0	0	$ 0	$ 0
Accounts receivable, net	0	0
Inventories	(1,076)	(1,146)
Deferred income tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	(1,076)	(1,146)
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	(4,726,347)	(4,494,004)
Investment in subsidiary	(2,963,912)	(2,839,674)
Total Assets	(7,691,335)	(7,334,824)
Current liabilities
Accounts payable	0	0
Accrued interest payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	(4,726,347)	(4,494,004)
Total Liabilities	(4,726,347)	(4,494,004)
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	(2,486,556)	(2,486,557)
Treasury stock, at cost	0	0
Accumulated other comprehensive loss, net of tax	89,922	70,236
Retained earnings (accumulated deficit)	(568,354)	(424,499)
Total Stockholders' Equity	(2,964,988)	(2,840,820)
Total Liabilities and Stockholders' Equity	$ (7,691,335)	$ (7,334,824)

Condensed Consolidating Finan82

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Operating Activities
Net income (loss)	$ 27,995	$ 21,293	$ 85,971	$ 54,488
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			17,478	11,967
Gain on sale of asset				(1,133)
Deferred income taxes			31,591	19,517
Amortization of debt origination costs			5,433	5,904
Stock-based compensation costs			7,098	4,919
Loss on extinguishment of debt	0	0	451	0
Lease termination costs			0	1,125
(Gain) loss on sale or disposal of property and equipment			(36)	321
Equity in income of subsidiaries	0	0	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			2,453	2,113
Inventories			(7,114)	14,478
Prepaid expenses and other current assets			5,472	7,598
Accounts payable			(17,553)	(25,452)
Accrued liabilities			5,207	8,297
Net cash provided by operating activities			136,451	104,142
Investing Activities
Purchases of property and equipment			(2,540)	(3,700)
Proceeds from the sale of property and equipment			344	0
Proceeds from sale of business			0	18,500
Proceeds from sale of asset			0	10,000
Proceeds from Insight Pharmaceuticals working capital arbitration settlement			7,237	0
Intercompany activity, net				0
Net cash provided by (used in) investing activities			5,041	(802,857)
Financing Activities
Term loan borrowings				720,000
Term loan repayments			(50,000)	(80,000)
Borrowings under revolving credit agreement			15,000	124,600
Repayments under revolving credit agreement			(81,100)	(58,500)
Payments of debt origination costs			(4,211)	(16,072)
Proceeds from exercise of stock options			6,600	3,654
Proceeds from restricted stock exercises			544	57
Excess tax benefits from share-based awards			1,850	1,030
Fair value of shares surrendered as payment of tax withholding			(2,187)	(1,688)
Intercompany activity, net			0	0
Net cash (used in) provided by financing activities			(113,504)	693,081
Effects of exchange rate changes on cash and cash equivalents			(333)	(746)
Increase in cash and cash equivalents			27,655	(6,380)
Cash and cash equivalents - beginning of period			21,318	28,331
Cash and cash equivalents - end of period	48,973	21,951	48,973	21,951
Prestige Brands Holdings, Inc.
Operating Activities
Net income (loss)	27,995	21,293	85,971	54,488
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			3,032	2,381
Gain on sale of asset				0
Deferred income taxes			148	(69)
Amortization of debt origination costs			0	0
Stock-based compensation costs			7,057	4,919
Loss on extinguishment of debt			0
Lease termination costs				0
(Gain) loss on sale or disposal of property and equipment			0	0
Equity in income of subsidiaries	(27,711)	(20,462)	(84,458)	(53,718)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			0	466
Inventories			0	0
Prepaid expenses and other current assets			3,557	5,821
Accounts payable			(33)	(2,460)
Accrued liabilities			(102)	1,010
Net cash provided by operating activities			15,172	12,838
Investing Activities
Purchases of property and equipment			(1,741)	(3,167)
Proceeds from the sale of property and equipment			0
Proceeds from sale of business				0
Proceeds from sale of asset				0
Proceeds from Insight Pharmaceuticals working capital arbitration settlement			0
Intercompany activity, net				0
Net cash provided by (used in) investing activities			(1,741)	(3,167)
Financing Activities
Term loan borrowings				0
Term loan repayments			0	0
Borrowings under revolving credit agreement			0	0
Repayments under revolving credit agreement			0	0
Payments of debt origination costs			0	0
Proceeds from exercise of stock options			6,600	3,654
Proceeds from restricted stock exercises			544	57
Excess tax benefits from share-based awards			1,850	1,030
Fair value of shares surrendered as payment of tax withholding			(2,187)	(1,688)
Intercompany activity, net			2,127	(23,093)
Net cash (used in) provided by financing activities			8,934	(20,040)
Effects of exchange rate changes on cash and cash equivalents			0	0
Increase in cash and cash equivalents			22,365	(10,369)
Cash and cash equivalents - beginning of period			11,387	24,644
Cash and cash equivalents - end of period	33,752	14,275	33,752	14,275
Prestige Brands, Inc., the issuer or the borrower
Operating Activities
Net income (loss)	25,153	19,699	78,127	52,830
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			444	446
Gain on sale of asset				0
Deferred income taxes			164	1,814
Amortization of debt origination costs			5,433	5,904
Stock-based compensation costs			0	0
Loss on extinguishment of debt			451
Lease termination costs				0
(Gain) loss on sale or disposal of property and equipment			0	0
Equity in income of subsidiaries	(15,898)	(12,977)	(52,599)	(33,700)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			1,158	(131)
Inventories			(2,519)	5,381
Prepaid expenses and other current assets			(305)	(140)
Accounts payable			(1,161)	(2,652)
Accrued liabilities			(1,636)	2,392
Net cash provided by operating activities			27,557	32,144
Investing Activities
Purchases of property and equipment			(93)	0
Proceeds from the sale of property and equipment			0
Proceeds from sale of business				0
Proceeds from sale of asset				0
Proceeds from Insight Pharmaceuticals working capital arbitration settlement			0
Intercompany activity, net				(809,157)
Net cash provided by (used in) investing activities			(93)	(809,157)
Financing Activities
Term loan borrowings				720,000
Term loan repayments			(50,000)	(80,000)
Borrowings under revolving credit agreement			15,000	124,600
Repayments under revolving credit agreement			(81,100)	(58,500)
Payments of debt origination costs			(4,211)	(16,072)
Proceeds from exercise of stock options			0	0
Proceeds from restricted stock exercises			0	0
Excess tax benefits from share-based awards			0	0
Fair value of shares surrendered as payment of tax withholding			0	0
Intercompany activity, net			92,847	86,985
Net cash (used in) provided by financing activities			(27,464)	777,013
Effects of exchange rate changes on cash and cash equivalents			0	0
Increase in cash and cash equivalents			0	0
Cash and cash equivalents - beginning of period			0	0
Cash and cash equivalents - end of period	0	0	0	0
Combined Subsidiary Guarantors
Operating Activities
Net income (loss)	18,147	14,058	58,860	34,884
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			13,686	8,682
Gain on sale of asset				(1,133)
Deferred income taxes			31,301	17,900
Amortization of debt origination costs			0	0
Stock-based compensation costs			0	0
Loss on extinguishment of debt			0
Lease termination costs				1,125
(Gain) loss on sale or disposal of property and equipment			0	0
Equity in income of subsidiaries	(2,033)	(1,654)	(6,868)	(2,565)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			2,188	6,556
Inventories			(3,014)	8,109
Prepaid expenses and other current assets			2,752	2,070
Accounts payable			(14,613)	(21,748)
Accrued liabilities			5,439	2,978
Net cash provided by operating activities			89,731	56,858
Investing Activities
Purchases of property and equipment			(212)	(419)
Proceeds from the sale of property and equipment			0
Proceeds from sale of business				18,500
Proceeds from sale of asset				10,000
Proceeds from Insight Pharmaceuticals working capital arbitration settlement			7,237
Intercompany activity, net				731,166
Net cash provided by (used in) investing activities			7,025	9,581
Financing Activities
Term loan borrowings				0
Term loan repayments			0	0
Borrowings under revolving credit agreement			0	0
Repayments under revolving credit agreement			0	0
Payments of debt origination costs			0	0
Proceeds from exercise of stock options			0	0
Proceeds from restricted stock exercises			0	0
Excess tax benefits from share-based awards			0	0
Fair value of shares surrendered as payment of tax withholding			0	0
Intercompany activity, net			(96,756)	(65,950)
Net cash (used in) provided by financing activities			(96,756)	(65,950)
Effects of exchange rate changes on cash and cash equivalents			0	0
Increase in cash and cash equivalents			0	489
Cash and cash equivalents - beginning of period			0	0
Cash and cash equivalents - end of period	0	489	0	489
Combined Non-Guarantor Subsidiaries
Operating Activities
Net income (loss)	2,033	1,654	6,868	2,565
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			316	458
Gain on sale of asset				0
Deferred income taxes			(22)	(128)
Amortization of debt origination costs			0	0
Stock-based compensation costs			41	0
Loss on extinguishment of debt			0
Lease termination costs				0
(Gain) loss on sale or disposal of property and equipment			(36)	321
Equity in income of subsidiaries	0	0	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			(893)	(4,778)
Inventories			(1,511)	692
Prepaid expenses and other current assets			(532)	(153)
Accounts payable			(1,746)	1,408
Accrued liabilities			1,506	1,917
Net cash provided by operating activities			3,991	2,302
Investing Activities
Purchases of property and equipment			(494)	(114)
Proceeds from the sale of property and equipment			344
Proceeds from sale of business				0
Proceeds from sale of asset				0
Proceeds from Insight Pharmaceuticals working capital arbitration settlement			0
Intercompany activity, net				77,991
Net cash provided by (used in) investing activities			(150)	(114)
Financing Activities
Term loan borrowings				0
Term loan repayments			0	0
Borrowings under revolving credit agreement			0	0
Repayments under revolving credit agreement			0	0
Payments of debt origination costs			0	0
Proceeds from exercise of stock options			0	0
Proceeds from restricted stock exercises			0	0
Excess tax benefits from share-based awards			0	0
Fair value of shares surrendered as payment of tax withholding			0	0
Intercompany activity, net			1,782	2,058
Net cash (used in) provided by financing activities			1,782	2,058
Effects of exchange rate changes on cash and cash equivalents			(333)	(746)
Increase in cash and cash equivalents			5,290	3,500
Cash and cash equivalents - beginning of period			9,931	3,687
Cash and cash equivalents - end of period	15,221	7,187	15,221	7,187
Consolidation, Eliminations
Investing Activities
Proceeds from Insight Pharmaceuticals working capital arbitration settlement			0
Consolidation, Eliminations
Operating Activities
Net income (loss)	(45,333)	(35,411)	(143,855)	(90,279)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			0	0
Gain on sale of asset				0
Deferred income taxes			0	0
Amortization of debt origination costs			0	0
Stock-based compensation costs			0	0
Loss on extinguishment of debt			0
Lease termination costs				0
(Gain) loss on sale or disposal of property and equipment			0	0
Equity in income of subsidiaries	45,642	35,093	143,925	89,983
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			0	0
Inventories			(70)	296
Prepaid expenses and other current assets			0	0
Accounts payable			0	0
Accrued liabilities			0	0
Net cash provided by operating activities			$ 0	0
Investing Activities
Purchases of property and equipment				0
Proceeds from the sale of property and equipment			$ 0
Proceeds from sale of business				0
Proceeds from sale of asset				0
Intercompany activity, net				0
Net cash provided by (used in) investing activities			0	0
Financing Activities
Term loan borrowings				0
Term loan repayments			0	0
Borrowings under revolving credit agreement			0	0
Repayments under revolving credit agreement			0	0
Payments of debt origination costs			0	0
Proceeds from exercise of stock options			0	0
Proceeds from restricted stock exercises			0	0
Excess tax benefits from share-based awards			0	0
Fair value of shares surrendered as payment of tax withholding			0	0
Intercompany activity, net			0	0
Net cash (used in) provided by financing activities			0	0
Effects of exchange rate changes on cash and cash equivalents			0	0
Increase in cash and cash equivalents			0	0
Cash and cash equivalents - beginning of period			0	0
Cash and cash equivalents - end of period	$ 0	$ 0	0	0
Insight Pharmaceuticals
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired			0	(749,666)
Acquisition of the Hydralyte brand			0	(749,666)
Insight Pharmaceuticals | Prestige Brands Holdings, Inc.
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired				0
Acquisition of the Hydralyte brand				0
Insight Pharmaceuticals | Prestige Brands, Inc., the issuer or the borrower
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired				0
Acquisition of the Hydralyte brand				0
Insight Pharmaceuticals | Combined Subsidiary Guarantors
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired				(749,666)
Acquisition of the Hydralyte brand				(749,666)
Insight Pharmaceuticals | Combined Non-Guarantor Subsidiaries
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired				0
Acquisition of the Hydralyte brand				0
Insight Pharmaceuticals | Consolidation, Eliminations
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired				0
Acquisition of the Hydralyte brand				0
Hydralyte
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired			0	(77,991)
Acquisition of the Hydralyte brand			$ 0	(77,991)
Hydralyte | Prestige Brands Holdings, Inc.
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired				0
Acquisition of the Hydralyte brand				0
Hydralyte | Prestige Brands, Inc., the issuer or the borrower
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired				0
Acquisition of the Hydralyte brand				0
Hydralyte | Combined Subsidiary Guarantors
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired				0
Acquisition of the Hydralyte brand				0
Hydralyte | Combined Non-Guarantor Subsidiaries
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired				(77,991)
Acquisition of the Hydralyte brand				(77,991)
Hydralyte | Consolidation, Eliminations
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired				0
Acquisition of the Hydralyte brand				$ 0

Subsequent Events (Details)

Subsequent Events (Details) $ in Millions	6 Months Ended
	Jun. 30, 2016USD ($)
DenTek Oral Care, Inc. | Scenario, Forecast
Subsequent Event [Line Items]
Purchase price of acquisition	$ 0